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ABSTRACT 
Dependence on petroleum for energy and petrochemical products has led to high 
energy costs, a polluted environment, the depletion of a finite resource (oil), and the 
reliance on hostile nations for our energy security.  Biofuels promise to alleviate some or 
all of these issues but remain costly and inefficient to produce, and difficult to integrate 
into our existing transportation infrastructure.  A renewable fuel molecule capable of 
replacing petroleum for our fuel and chemical industries is desired.  Isobutene is an 
important commercial chemical used for the synthesis of butyl rubber, terephthalic acid, 
specialty chemicals, and a gasoline performance additive known as alkylate.  Currently, 
isobutene is produced from petroleum and hence is nonrenewable. Here we report that the 
Saccharomyces cerevisiae mevalonate diphosphate decarboxylase (ScMDD) can convert 
3-hydroxy-3-methylbutyrate (3-HMB) to isobutene. Whole cells of Escherichia coli 
producing ScMDD formed isobutene from 3-HMB at a rate of 154 pmol h-1 g cells-1. 
His6-ScMDD was purified by nickel affinity chromatography and shown to produce 
isobutene from 3-HMB at a rate of 1.33 pmol min-1 mg-1 protein. In contrast, no 
isobutene was detected from control cells lacking ScMDD, and controls showed that both 
His6-ScMDD and 3-HMB were required for detectable isobutene formation in enzyme 
assays.  ScMDD was subjected to error-prone PCR and 2 improved variants were 
characterized, ScMDD1 (I145F) and ScMDD2 (R74H). Whole cells of E. coli producing 
ScMDD1 and ScMDD2 produced isobutene from 3-HMB at rates of 3000 and 5888 pmol 
h-1 g cells-1 which are 19- and 38-fold increases compared to cells producing His6-
ScMDD.  Although ScMDD was shown to be amenable to manipulation in order to 
xii 
 
 
increase its activity on 3-HMB, we estimate that a 106 fold increase in activity is needed 
for commercial application.  Two novel methods were designed to increase enzyme 
activity—a mevalonate selection and an isobutene biosensor. 
The mevalonate selection yielded one variant with a 3.9-fold increase in isopentenol 
production from mevalonate over wild-type, to 186.6 nmol min-1 g cells-1, as well as a 
51.6% increase in isobutene-formation.  The isobutene biosensor was built and confirmed 
to respond to isobutene, toluene, and isoprene with induction ratios of 1.64, 3.58, and 1.3, 
respectively. 
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Chapter 1. Introduction 
 
I. Dependence on fossil fuels 
Globalization has brought the world into the 21st Century, where the united effort 
of many nations has improved the standard of living for millions of lives.  However, this 
improved standard of living has come at a significant cost, especially where energy 
discovery, development, and consumption are concerned.  Energy, particularly in the 
form of petroleum, has become the world’s currency.  Fortune Magazine’s top 10 largest 
companies in the world include six companies with a vested interest in fossil fuel 
discovery and development; Shell [2], Exxon Mobil [3], British Petroleum [4], Sinopec 
[5], China National Petroleum [6], and Chevron [10] (19).  The United States (US) 
consumed 360 billion gallons of petroleum in 2008, while domestically producing only 
76 billion gallons.  The difference is made up in imports, which cost the US over $250 
billion each year (116, 117).  Reducing the US dependence on petroleum consumption 
will mitigate the cost of importation and, therefore, will help provide a more fiscally 
sound and independent country.  
The United States is compelled to import petroleum, not only for transportation-
related activities, but for use in the chemical industry as well.  According to the US 
Energy Information Administration, approximately 47% of imported petroleum is used to 
produce gasoline, where the remainder is used to provide feedstocks for the chemical 
synthesis of rubber, plastic, polymers, food additives, etc. (118).  Petroleum usage creates 
other problems as well.  It is a non-renewable energy source, when burned it deleteriously 
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impacts the environment through greenhouse gas emissions such as carbon dioxide (14), 
and our dependence on petroleum is a national security issue.   
The International Energy Agency (IEA) stated that production of conventional 
crude oil peaked in 2006 (17).  Peak oil is the point in time when the maximum rate of 
global petroleum extraction is reached, after which the rate of production enters a 
terminal decline (111).  Pessimistic predictions indicate that crude oil supplies may be 
completely utilized within this generation.  Current understanding of the genesis of oil is 
that coal, oil, and natural gas were formed many eons ago through the transformation of 
plant and animal residues buried deep underground (11).  Since the utilization of fossil 
fuels takes a fraction of the time it took to create it, many estimate that this finite resource 
could run out within the next few generations.  Even considering optimistic projections, 
the fact still remains that petroleum is a finite, non-renewable commodity that requires an 
alternative(s).   
Aside from supply issues, the production and utilization of petroleum poses an 
environmental risk.  The negative environmental impacts of fossil fuels are widespread 
and can occur at the local, regional, and global levels (11).  For example, the extraction of 
oil can pollute the environment, which was seen in the Exxon Valdez oil spill in 1989 as 
well as the British Petroleum disaster in the Gulf of Mexico in 2010.    Regional risks to 
the environment include acid rain, which is caused by sulfur dioxide and nitrogen oxides 
created during combustion.  Burning fossil fuels also increases the incidence of asthma 
attacks in areas with high car volume (81).  And on a global scale, the burning of fossil 
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fuels results in the release of potent greenhouse gases such as carbon dioxide, which is 
contributing to global climate change (14).   
Our addiction to petroleum also obligates us to deal with the countries and 
governments that control the oil.  This was seen clearly in the Arab Oil Embargo in 1974 
when several Middle Eastern nations refused to sell petroleum to the United States with 
the intention of influencing US foreign policy in the region (11).  Ultimately, the oil-
exporting nations began selling oil again when the US adopted several energy efficiency 
and renewable energy policies that significantly reduced the only source of income for 
these oil-rich nations.  However, the interdependence between oil-exporting and oil-
importing nations was made clear during this crisis by the rapid increase in the price of 
oil and a severe economic crisis associated with it (11).  We rely on oil to sustain our 
economy and our military, and so our dependence on imported oil is a national security 
issue.   
 
II. Reducing our dependence through biofuels 
Considering all of the problems associated with petroleum, there is a clear 
impetus for alternative, biorenewable strategies to produce both fuels and chemicals that 
will reduce our dependence on foreign oil, provide cleaner alternatives to petroleum, 
provide jobs, and increase exports.  In an attempt to solve the problems associated with 
petroleum small but significant steps have been made in biofuels production such as 
ethanol, which is intended to offset our gasoline usage.  The production of biofuels, a 
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renewable resource, is not a new idea.  In fact, the first widely produced and purchased 
automobile was the Ford Model-T, which was produced in 1908 and designed to run on 
gasoline or ethanol.  And biorenewable resources, which are organic materials of recent 
biological origin, have historically been used for a wide variety of purposes, from fuels to 
building materials, chemicals, and fibers (6).  Thousands of years ago wood-burning fires 
were used for heat and cooking, and grass-fed horses and cattle were used for farming 
and transportation needs.  Although fossil fuels currently dominate our fuels and 
chemicals infrastructure, it was only in the last 150 years that the transition away from 
biomass occurred (11).  It is at this point that the world looks to return to a bio-based fuel 
and chemical industry.  However, it is clear from past experience that to compete with 
fossil fuels, the bio-based alternatives must be made in a cheap and efficient process. 
Ethanol, currently made in large quantities from corn or sugar cane, has quickly 
become a significant component of our transportation fuels.  According to the Renewable 
Fuels Association, ethanol production in the United States has increased from 5.9 billion 
gallons in 2007 to 13.6 billion gallons in 2010 (90).  Currently, the total gasoline 
consumption in the US is around 137 billion gallons, indicating that we are producing 
nearly 10% of our gasoline demand as ethanol, on a volumetric basis.  Since the majority 
of cars can only tolerate a 10% ethanol blend in gasoline, producers will have to find 
ways of developing new markets either through exports or by increasing the number of 
Flex-Fuel vehicles capable of tolerating greater amounts of ethanol.  This highlights a 
major drawback of using ethanol and illustrates how a fuel that could be used in 
conventional combustion engines at higher concentrations would be an advantage.   
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With that said, domestically produced ethanol’s benefits go beyond simply 
displacing gasoline and diminishing the need for costly imports.  It reduces our 
dependence on foreign oil, which improves our national security by diminishing our 
reliance on governments that may be hostile to our interests.  Also, the production of 
corn-based ethanol reduces the amount of greenhouse gas emissions over gasoline 
production by 19% (29, 122).  In more modern ethanol plants that use natural gas or 
biomass for power instead of coal, the greenhouse gas emissions savings are even 
greater—up to 50% (29, 122). 
Although ethanol has made significant progress in diminishing our dependence on 
petroleum, as well as lowering GHG emissions, there are several issues with ethanol as a 
fuel.  One of the largest constraints in producing corn-based ethanol is the maximum 
volume that can be produced.  If the entire US corn crop were converted to ethanol, it 
would only provide the energy density to displace about 12% of our transportation 
demand (48).  Additionally, the primary crops used for ethanol production, corn and 
sugar cane, can be produced only in certain regions of the US and the world.  The solid 
state of biomass reduces the ability to transport it over large distances in a cost-effective 
manner.  For this reason, the ethanol plants producing ethanol from corn and sugarcane 
must be set up in rural areas where the feedstock is produced.  The ethanol must then be 
transported to the larger markets found in urban areas.  An efficient solution would be to 
transport the ethanol in existing gasoline pipelines, but ethanol’s hygroscopicity leads to 
corrosion in these lines and would necessitate new pipelines dedicated to ethanol 
transport (36).  Another problem associated with ethanol is its lower energy density.  
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Approximately 1.4 gallons of ethanol is needed to have the same energy as 1 gallon of 
gasoline (11).   
Another disadvantage for ethanol to overcome is the energy and cost associated 
with distillation.  Distillation is the process by which mixtures are separated by their 
differences in boiling points.  In order to concentrate and purify the ethanol, it must be 
boiled away from the water at over 78°C, which requires a large amount of energy.  Some 
estimates indicate that as much as 58% of the energy used at an ethanol plant is used in 
the distillation of ethanol (71).  Overcoming the need for distillation, such as by 
producing a volatile product, may significantly reduce the cost and energy required in 
biofuels production.  
 
III. Alternative biofuels 
Several research groups and companies have attempted to overcome ethanol’s 
limitations by producing alternative biofuels (27, 41, 47, 59, 85, 95, 104, 129).  These 
fuels include longer-chain alcohols and hydrocarbons that may have more desirable 
characteristics than ethanol, such as a higher energy density.  However, at this point, the 
technology to produce these biofuels is not economically viable.  Many of these products 
are not volatile and so still require distillation or a costly alternative purification method 
such as membrane filtration or gas stripping.  The boiling points of many of these 
alternative biofuels are often higher than ethanol’s boiling point, which further increases 
the energy and cost associated with distillation.  Finally, many of these alternative 
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biofuels, such as 1-butanol, are toxic to their producer organism, which inhibits cell 
growth even at low concentrations and in turn drives up costs.  Butanol is toxic to E. coli 
at a concentration of 1.5% (v/v) (37), whereas the primary organism used to produce 
ethanol, yeast, can tolerate as much as 20%.  Since butanol is toxic at lower 
concentrations than ethanol, the amount of product obtained is low.  These issues need to 
be addressed, possibly through the production of a volatile product, in order for 
alternative biofuels to be adopted on an industrial scale. 
With all of the issues illustrated above, it is clear that the search for an alternative 
to petroleum is imperative and is a difficult challenge facing scientists and engineers.  
The discovery of new and efficient pathways to produce petroleum-replacing compounds 
will be critical to overcoming these challenges. 
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Chapter 2. Literature Review 
 
Introduction: 
The production of corn ethanol is an important step towards biofuels 
development, but it comes with several problems.  To alleviate these problems, the 
production of alternative biofuels has been proposed.  However, although the list of 
biofuel target molecules may be diverse, a careful consideration of each is needed to 
ensure their efficient production.  One critical consideration is how the molecules will be 
produced.  The production of ethanol from Saccharomyces cerevisiae or Escherichia coli 
has been known for some time and was originally discovered as a natural product of 
fermentation.  The production of alternative biofuels and platform chemicals is 
complicated because many of the enzyme pathways needed to produce them have only 
recently been discovered, and often the production of these molecules bring 
complications of their own, such as toxicity to the producer organism.   
The use of microbes to produce fuels and platform chemicals is known as 
microbial engineering.  The task requires the elucidation of the desired pathway and its 
efficient expression in the host organism.  Pathway optimization is often required to 
improve carbon flux to the target molecule, and the key enzymes of these pathways 
require substantial optimization before commercial viability can be achieved.  Directed 
enzyme evolution is often done in a rational design or random mutagenesis fashion.  In 
either case, an efficient screening method or selection method is required to realize the 
needed enzyme activity increases.  The first step is to consider the pathways available to 
produce alternative fuels. 
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Alternative Biofuels Production: 
 
I. Butanol 
Longer chain alcohols and branched molecules often have improved 
characteristics over ethanol.  Butanol has been considered as a possible replacement for 
ethanol as a biofuel in the near-term.  It has an energy density of 27 MJ/L, which is closer 
to gasoline’s 32 MJ/L than ethanol’s 21 MJ/L (Table 1), and butanol also has lower 
solubility in water, which prevents the widespread corrosion seen with ethanol and allows 
butanol to be transported in pipelines with gasoline (41).  Additionally, butanol can be 
blended into gasoline and diesel engines at much higher content than ethanol (41).  
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TABLE 1. Energy density and octane ratings are critical to consider when comparing the 
production of various potential biofuels.  Listed are the specs for several molecules discussed in 
this report, as well as their energy density and octane values.  N/A is used to indicate molecules 
whose octane rating was unavailable. 
 
Another advantage is that butanol is naturally produced by some organisms, such 
as Clostridium acetobutylicum (41).  Specific butanol yields have been reported in some 
of the Clostridium species at 19.6 g/L (85).  Native butanol production occurs via the 
acetone-butanol-ethanol (ABE) fermentation where in order to produce 1 mol of butanol 
in Clostridium, 1 mol of glucose is required along with 4 mol of NADH.  However, the 
production of side-products acetone and ethanol in ABE fermentation limits total butanol 
yields.  Additionally, maximal yields in Clostridium, even through strain improvement, 
have resulted in only 19.6 g/L being produced in Clostridium beijernickii (85, 118).  This 
yield necessitates the further development and improvement of butanol biosynthesis.  
Fuel Image Octane Energy Density
Ethanol 112 21 MJ/L
N-butanol 96 27 MJ/L
Isobutanol 102 26.4 MJ/L
Gasoline Mixture 87 32 MJ/L
Isooctane 100 33 MJ/L
Isopentenol N/A 35 MJ/L
Isopentanol N/A 30.5 MJ/L
Isobutene N/A 26.5 MJ/L
OH
OH
OH
OH
OH
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Improvements are difficult in Clostridium due to the fact that they are strict anaerobes 
with relatively slow growth rates and limited tools for genetic manipulation (85). 
A more manageable system to develop butanol biosynthesis in is E. coli due to its 
high growth rate and established gene manipulation strategies.  In its first iteration, the 
pathway to produce 1-butanol from Clostridium acetobutylicum was heterologously 
expressed in E. coli (85).  This pathway mimics the Clostridium acetobutylicum pathway 
by expressing acetyl-CoA acetyltransferase (thl), 3-hydroxybutyryl-CoA dehydrogenase 
(hbd), crotonase (crt), butyryl-CoA dehydrogenase (bcd), and alcohol dehydrogenase 
(adh) (85) (Fig. 1).  With these genes expressed, E. coli produced 13.9 mg/L butanol (18, 
85).   
12 
 
 
 
FIG. 1. The native Clostridium pathway for butanol production.  The pathway is dominated by 
NADH oxidation and uses the acetyl-CoA acetyltransferase (atoB/thl), 3-hydroxybutyryl-CoA 
dehydrogenase (hbd/phaB), crotonase (crt), butyryl-CoA dehydrogenase (bcd/ccr), and alcohol 
dehydrogenase (adh) for butanol production.  
 
These low production numbers were increased by replacing the Clostridium 
acetyl-CoA acetyltransferase (thl) with E. coli’s acetyl-CoA acetyltransferase (atoB) in 
2 Acetyl-CoA
Acetoacetyl-CoA
CoA
atoB, 
thl
NADH
NAD+
hbd, 
phaB
3-Hydroxybutyryl-CoA
H2O
crt
Crotonyl-CoA
NAD+
bcd, 
ccr
Butyryl-CoA
adhE2/
adhE1
n-butanol
NAD+
NADH
NADH
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order to increase acetoacetyl-CoA pools (85).  Additional strain improvement was made 
by knocking out pathways that competed for NADH and acetyl-CoA such as E. coli’s 
lactate dehydrogenase, alcohol dehydrogenase, and fumarate reductase.  The optimized E. 
coli strain was capable of a 1-butanol titer of 550 mg/L (18).  Additional work using 
multiple promoters for the heterologously expressed genes resulted in 1.2 g/L butanol 
production (50).  This level of butanol production corresponds to roughly 7.2% 
theoretical yield (85).  At this point, Atsumi et al. had identified that E. coli’s natural 
butanol tolerance is 1.5%, which is similar to reports for C. acetobutylicum (69), 
indicating that a maximal increase up to approximately 10 g/L or 15 g/L is possible in 
unmodified E. coli (85). 
Further improvement in butanol production was recently achieved in E. coli 
through two methods.  The first is an innovative way to increase flux through a modified 
Clostridium 1- butanol pathway expressed in E. coli (100), while in the second method, 
E. coli was engineered to reverse the β-oxidation pathway (26).  Some of the highest 
titers seen for 1-butanol were achieved in E. coli through the expression of a modified 
Clostridium 1-butanol pathway gene, trans-enoyl-CoA reductase (Ter), which is an 
irreversible reaction (100).  With Ter alone, Shen et al. reports that 1-butanol titers reach 
approximately 3 g/L, which is 10-fold less than the maximal production levels that are 
reached when the pathway is optimized to harness NADH and acetyl-CoA pools to direct 
flux through the pathway.  With these additions, titers of 30 g/L have been achieved in E. 
coli, which is 70 to 88% of theoretical yield (100).  Although this value is higher than the 
toxicity level for E. coli, this level was achieved through the in-situ removal of 1-butanol 
during production (100).   
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Dellomonaco et al. took a different approach to increase butanol production.  In 
their work, the β-oxidation cycle is reversed to produce linear n-alcohols and long-chain 
fatty acids at high efficiency.  The pathway efficiency was increased due to the direct 
addition of acetyl-CoA for acyl-chain elongation, rather than requiring the ATP-
dependent activation to malonyl-CoA, which is seen in fatty acid biosynthesis.  With this 
system, 1-butanol was produced at 14 g/L in E. coli (26).  Using the reverse β-oxidation 
pathway is more efficient than using fatty acid biosynthesis or keto-acid derived 
molecules (described below).  The theoretical yield of n-hexanol from glucose using the 
reverse β-oxidation pathway is 66.7%, compared to the maximum theoretical yield in the 
keto-acid pathway, which is 50% (26).  
             Although the reverse β-oxidation pathway might be more efficient, using the 
keto-acid pathway might produce more attractive biofuels.  It was observed that several 
important alcohols, n-butanol among them, were produced in Saccharomyces cerevisiae 
by degradation of amino acid biosynthetic intermediates via the Ehrlich pathway (18, 85) 
(Fig. 2).   
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FIG. 2.  The non-fermentative isobutanol production pathway engineered into E. coli.  This 
pathway utilizes acetolactate synthase (ilvH/AlsS), acetohydroxy acid isomeroreductase (ilvC), 
dihydroxy acid dehydratase (ilvD), 2-ketoacid decarboxylase (KDC), and alcohol dehydrogenase 
(ADH). 
 
In this non-fermentative pathway, keto acid intermediates are converted into the 
alcohol by decarboxylation into an aldehyde before reduction to the alcohol (18).  A 2-
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keto acid decarboxylase from Lactococcus lactis with high substrate promiscuity, along 
with an alcohol dehydrogenase from S. cerevisiae, was heterologously expressed in E. 
coli.  This expression system resulted in the production of several products, due to the 
wide substrate specificity of the heterologously expressed enzymes, including 1-
propanol, isobutanol, 1-butanol, 2-methyl-1-butanol, 3-methyl-1-butanol, and 2-
phenylethanol (18).  More specifically, isobutanol and 1-butanol titers were 389 mg/L 
and 16 mg/L, respectively (85).   
At this stage, the total yield was still low and the promiscuity of the 
decarboxylase led to a mixture of alcohols being produced (85).  Isobutanol became the 
primary target because it has many of the benefits that 1-butanol has, such as a high 
energy density (26.4 MJ/L), but its branched chain enhances its use as a fuel molecule 
due to higher octane ratings and the branching lowers the boiling point, which can make 
distillation of the product cheaper and less energy intensive (39).  The yield of isobutanol 
was improved by overexpressing E. coli ilvHCD genes, which increased the amount of 2-
ketoisovalerate available for decarboxylation.  This modification allowed for 1.5 g/L of 
isobutanol to be produced in E. coli (85).  Additional changes, including knocking out the 
pyruvate formate lyase (pflB) gene, which competes for pyruvate, resulted in 22 g/L of 
isobutanol production (85).  This is about 86% of the theoretical yield (85).  However, 
there are several hurdles to overcome in the production of butanol, such as butanol’s 
toxicity to the organism that produces it.  This leads to lower titers, which increases the 
energy and cost required for product distillation.  Additionally, butanol has a higher 
boiling point than ethanol, which increases energy and costs if distillation is used (41). 
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II. Microbial hydrocarbon production 
An improved renewable fuel target over ethanol and isobutanol is to produce a 
gasoline substitute.  Gasoline is a mixture of many different compounds, but mainly 
includes C4 to C12 hydrocarbons (85).  The enzymatic pathways needed for alkene and 
alkane production are only recently becoming more clearly understood.  Hydrocarbons 
are produced naturally in microorganisms for such things as cell membrane formation 
and biofilm production, but their production presents several problems to microbial 
metabolism.  The reduced alkanes often come at a high price, both to produce and to 
utilize.   
While alkene and alkane biosynthesis on an industrial scale may be difficult, these 
compounds are present throughout nature.  Alkane production from fatty acid metabolites 
has been observed in the production of plant cuticular waxes and insect pheromones (95).  
However, the method of alkane production has remained in dispute.  Three possible 
routes to microbial alkane production have been proposed – the first is through the 
decarboxylation of a fatty acid, the second is the decarbonylation of an aldehyde, and the 
third is through head-to-head condensation (62).  In each of these cases, the general 
precursors proposed for alkene and alkane production have been fatty acid intermediates 
(85, 99). 
 
III. Fatty acid biosynthesis 
In fatty acid biosynthesis, the addition of two carbon units to a fatty acyl chain 
results in a diversified pool of fatty acids depending on when the chain elongation is 
terminated.  The process begins with the production of malonyl-CoA from acetyl-CoA 
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and bicarbonate catalyzed by acetyl-CoA carboxylase (85) (Fig. 3).  Next, malonyl-CoA 
is converted to malonyl-ACP via malonyl transacylase.  Elongation then occurs via β-
ketoacyl synthase, which condenses acetyl-CoA and malonyl-ACP to form acetoacetyl-
ACP (85).  Acetoacetyl-ACP is then reduced by β-ketoacyl-ACP reductase, dehydrated 
by β-hydroxyacyl-ACP dehydratase, and then reduced again by enoyl-ACP reductase to 
form butyryl-ACP (85).  This elongation process is then repeated until the fatty acid 
biosynthesis is terminated using a thioesterase, which hydrolyzes the fatty acyl-ACP to 
form a free fatty acid, in eukaryotes, or the fatty acid is transferred to glycerol-3-
phosphate in prokaryotes (85). 
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FIG. 3. The fatty-acid biosynthetic pathway is shown.  The pathway is catalyzed by acetyl-CoA 
carboxylase (ACC), transacylase (MT), β-ketoacyl synthase (KS), β-ketoacyl-ACP reductase 
(KR), β-hydroxyacyl-ACP dehydratase (HD), enoyl-ACP reductase (ER), and thioesterase (TE).  
From there, the fatty acid can be decarboxylated via a decarboxylase to an alkene or alkane, or it 
can be converted to a fatty acyl-CoA via an acyl-CoA synthetase (fadD). Next, the acyl-CoA is 
reduced and decarbonylated to an alkane.  On the right is a biological example of the aldehyde 
decarbonylase where octadecanal is decarbonylated to form heptadecane. 
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In order to produce biofuels from fatty acids, the fatty acids need to be produced 
in great abundance.  One study knocked out the fadD gene in E. coli, which resulted in 
three-fold more fatty acids (255 nmol/L) over wild-type by preventing degradation (85).  
In this fadD knockout background, the acyl-ACP thioesterase from Cinnamonum 
camphorum was heterologously expressed and yielded 511 nmol/L (a two-fold increase) 
(85).  Additional heterologous expression under fermentation conditions yielded as much 
as 2.5 g/L (85).  With fatty acid production being optimized in E. coli, other groups 
turned to uncovering the enzyme systems that would convert the fatty acids into 
hydrocarbon fuel molecules.    
 
IV. Alkane biosynthesis 
The decarbonylation of a fatty aldehyde to an alkane was shown in microsomal 
preparations of Botyrococcus braunii (28).  This activity was first uncovered by 
inhibiting hydrocarbon biosynthesis using a thiol compound such as dithioerythritol 
(DTE) (12) and observing the accumulation of aldehydes with n + 1 carbon lengths 
compared to the hydrocarbons.  The possibility of the decarbonylation of an aldehyde as 
the immediate precursor to an alkane was not recognized until the discovery of a 
porphyrin-coordinated Ru complex capable of this reaction (4, 28, 34).  This enzyme was 
shown to decarbonylate octadecanal into heptadecane with the concomitant production of 
carbon monoxide (28) (Fig. 3).  This decarbonylase pathway to microbial alkane 
biosynthesis was also seen in cyanobacteria (99).  This pathway converts fatty acids into 
fatty aldehydes via an acyl-acyl carrier protein reductase and then decarbonylates the 
aldehyde into an alkane or alkene (99).  Heterologous expression of this two enzyme 
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system in E. coli led to the production of C13 and C17 mixtures of alkanes and alkenes 
(99).  Although work to uncover the reaction pathway of fatty acids into alkanes and 
alkenes is significant, these products tended to be middle-chain alkanes and susceptible to 
the problems described previously, such as difficulty in product purification and host 
toxicity (58).   
 
V. Ethylene 
Volatile hydrocarbon products have been proposed as a way to overcome product 
toxicity and high purification costs, and several reports have indicated that the production 
of volatile, short-chain hydrocarbons is possible from biological sources  (43, 62).  This 
includes the production of ethylene, which has been produced via three pathways: the 
ACC pathway, the KMBA pathway, and the EFE pathway (62) (Fig. 4).  The ACC 
pathway is found in many plant species but is rare in microorganisms.  In this pathway, 
S-adenosyl methionine (SAM) is produced from methionine via SAM synthase.  SAM is 
then converted to ACC by ACC synthase before the ACC is converted to ethylene by an 
ACC oxidase.  In the KMBA pathway, which is common in microorganisms, methionine 
is converted to KMBA via a transaminase (62).  Hydroxyl radicals then convert the 
KMBA to ethylene.  And in the EFE or ethylene-forming enzyme pathway, which has 
been found in fungi and bacteria, 2-oxoglutarate is converted directly to ethylene (62).  
This enzyme was heterologously expressed in E. coli and produced ethylene at a rate of 
11.78 mg h-1 g of cells-1 (51).  More recent work has cloned several copies of the EFE 
gene into Pseudomonas putida and found ethylene production rates increased to 80.2 mg 
h-1 g of cells-1 (121).   
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FIG. 4. The three known biological pathways for ethylene biosynthesis.  In the ACC pathway, S-
adenosyl methionine (SAM) is produced from methionine via SAM synthase.  SAM is then 
converted to ACC by ACC synthase and then ACC oxidase converts ACC to ethylene.  In the 
KMBA pathway, a transaminase and xydroxyl radical converts methionine to KMBA and then 
ethylene.  And in the Ethylene-Forming Enzyme Pathway the ethylene forming enzyme (EFE) 
converts 2-oxoglutarate into ethylene.  
 
VI. Isobutene 
The focus of this thesis is isobutene.  This branched volatile alkene was chosen as 
a target because of its significant importance as a platform chemical – for the production 
of both fuels and industrial chemicals such as plastics and rubber.  Isobutene is currently 
the 25th most produced organic chemical in the US at 1.47 × 109 kg per year of annual 
production from petroleum (11).  Biological production of isobutene has been previously 
reported to naturally occur in a strain of fungi known as Rhodotorula minuta (43, 44).  
This activity was found to be via a cytochrome P450 and thought to be involved in the 
catabolic pathway of L-leucine, where-in 3-methylcrotonyl-CoA is produced and would 
then be converted to isobutene via the P450 enzyme.  It was also shown that the primary 
enzymatic activity occurred with isovaleric acid as the substrate (62) (Fig. 5).  This 
activity was first shown by Fujii et al. using a whole cell extract of Rhodotorula minuta 
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to convert isovaleric acid into isobutene requiring NADPH as the cofactor (43).  With 
this whole-cell extract, an isobutene-forming rate of 17 ng mg of protein-1 h-1 was 
measured (43).  It was later found that this enzyme is a benzoate 4-hydroxylase that acts 
in the β-ketoadipate pathway.  This pathway uses several steps to convert L-
phenylalanine first to β-ketoadipate, and then forms succinyl-CoA and acetyl-CoA that 
enter the TCA cycle (101).  Although this enzyme accomplished the biogenesis of 
isobutene, the cytochrome P450 enzyme is membrane associated and extremely difficult 
to improve through directed enzyme evolution.  At this point, to our knowledge, no rate 
improvement has been accomplished using this enzyme system. 
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FIG. 5. The biological production of isobutene using a benzoate 4-hydroxylase found in 
Rhodotorula minuta.  This activity is found using a leucine pathway intermediate as the substrate.  
This intermediate can also be used in the biosynthesis of mevalonate.  
 
The only other known biological route to produce isobutene is using the enzyme 
mevalonate diphosphate decarboxylase (MDD) (EC 4.1.1.33).  As part of this thesis I 
show that MDD has the ability to decarboxylate and dehydrate the non-native substrate 3-
hydroxy-3-methylbutyrate (3-HMB) into isobutene (46, 74).  MDD has several benefits 
over the benzoate 4-hydroxylase enzyme in terms of isobutene production.  These include 
the fact that MDD is a well characterized enzyme that has many known homologs, which 
helps in the identification of important active site residues.  Also MDD is a soluble 
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improving enzyme activity and expression easier.  This is necessary because the 
discovery of the activity of MDD to produce isobutene also came with the realization that 
the activity is much too low for any commercial application, and so methods to increase 
the enzyme’s activity needed to be developed. 
 
Optimizing enzyme function 
The discovery of the biological pathway to produce isobutene is only the first part 
in overcoming the problem of developing a biological route to renewable hydrocarbon 
production.  As mentioned above, the total yield and rate of isobutene production is quite 
low and so substantial improvement in MDD activity as well as metabolic engineering of 
the organism is required for the process to become a commercially viable system.  
Improving an enzyme’s catalytic properties can include two approaches – rational design 
or directed enzyme evolution (120)—which are often used in concert to achieve the 
intended goal.   
 
I. Rational design 
In a rational design approach, the enzyme fitness is improved through planned 
amino acid changes in the protein sequence that are introduced through site or region 
specific mutagenesis (120).  In this method, the investigator uses structural information of 
the protein and has an idea about the reaction mechanism in order to design a mutational 
strategy (120).  The sites targeted for mutation can be picked based on a variety of 
rationales, including the desire to improve enzyme stability, specificity, solubility, and 
binding affinity (120).  One example of using rational design to improve the enzyme 
26 
 
 
stability is to replace free cysteines in order to limit unwanted disulfide bond formation 
from occurring (120).  Aside from cysteine replacement, implementing rational design 
strategies are often very complex and can lead to unintended concequences.  One 
example of the complexeties of rational design was seen in the computationally directed 
deletion of two residues predicted to be key catalytic residues in a retroaldolase.  These 
deletions actually led to a five-fold increase in enzyme activity (63).  Although this 
example highlights the potential challenges with using rational design, it can be a fast and 
effective method to improve enzyme activity when a clear mutational target is known.  
However, the complexities involved in enzyme structure and activity make rational 
design a very difficult strategy to implement effectively (130).     
 
II. Directed enzyme evolution 
While rational design may be limited by the ability to accurately predict the 
functional significance of an amino acid residue, directed evolution overcomes this 
limitation by employing a more general approach.  This strategy parallels natural 
evolution where gene and protein level mutations are randomly added and a selection is 
applied to identify the target variants (120).  However, directed enzyme evolution has its 
own set of drawbacks.  The experimental design to build enough variants with enough 
sequence diversity can often be a problem and rate limiting.  Additionally, setting up an 
efficient selection method to isolate improved variants can often be extremely difficult, 
depending on the enzyme.  For this reason, researchers often attempt to use what is 
known as ‘semi-rational design’ (120).  In this method, aspects of both rational design 
and directed enzyme evolution are employed in order to isolate the desired variant (120).  
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A semi-rational approach was seen in the mutagenesis of the xylose reductase from 
Neurospora crassa (9).  The gene was subjected to mutagenesis, including site-saturation 
mutagenesis, as well as rational design via combinatorial active site-saturation testing 
(CASTing), which combined to produce a variant found with a nine-fold increase in 
activity (9).  In this example the methods used to introduce the required diversity and to 
select for improved variants were critical to the successful outcome. 
There are many ways to vary the target gene’s sequence, and the method is 
dictated by the level of mutagenesis desired as well as the desired level of design 
(between random and rational) used in the mutations.  Random diversity can be 
accomplished by disturbing DNA replication, either through chemical and physical 
mutation, using an E. coli strain engineered for high mutation rates, error-prone PCR, 
random insertion/deletion mutagenesis, or saturation mutagenesis (120).  If the work 
requires a tuned amount of random diversity at chosen positions, then the synthesis of 
oligonucleotides or even whole gene synthesis to incorporate that diversity is the best 
course.  Finally, several methods exist for diversity to be incorporated through 
recombination, both homologous and non-homologous (120).   
Chemical and physical methods are used to damage the DNA or cause replication 
errors to occur that change the sequence.  This method often incorporates the mutations 
randomly throughout the sequence, but the mutations can often be biased for certain 
residues.  For example, the chemical mutagen ethylenemethanesulfonate (EMS) is an 
alkylating agent that targets guanine bases and causes the GC base pair to be converted to 
an AT base pair (120).  This produces an error rate of between 5 × 10-4 to 5 × 10-2 
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mutations per gene.  So in this case, the diversity that could be produced by the 
conversion of an AT pair to a GC pair would not be realized.   
One widely used method for incorporating random diversity is to use a mutator 
strain.  E. coli K12 mutator strains, such as XL1-red (Stratagene), have been engineered 
to have a mutation rate 5,000 times higher than wild-type.  This change is due to the 
disruption of three DNA repair pathways: mutS, mutD, and mutT (120).  Often this 
method can be used in conjunction with an in vitro method to incorporate random 
diversity such as error-prone polymerase chain reaction (PCR).  In error-prone PCR, the 
inherent error rate in a polymerase such as Taq (1 mutation in 9000 bp) (112), is 
enhanced by the addition of manganese ions.  This replaces the natural cofactor, 
magnesium, which increases the error rate up to 8 mutations per 1000 bp (Clontech 
manual).  This rate can be increased further, if necessary, by the inclusion of a nucleotide 
mixture containing a greater amount of one nucleotide (such as dGTP), which leads to 
misincorporation of the guanine and results in a mutation. 
One of the limitations of error-prone PCR is that often the only changes are one 
nucleotide per codon.  So, on average only 5 out of 19 possible amino acid variants can 
be created with this method (120).  One alternative is to use sequence saturation 
mutagenesis (SESAM) in order to incorporate all four natural nucleotides into a given 
site  (120).  The method is comprised of four steps: a step to amplify the target gene with 
random lengths, incorporation of a universal base (deoxyinosine, dITP), elongating the 
gene to full length using PCR, and then replacing the dITP with one of the four standard 
bases (128). 
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Another method to randomly incorporate diversity is through random insertions or 
deletions.  This is exemplified in the diversity generated through transposons, which 
often includes the incorporation or deletion of multiple bases at a time.  In pentapeptide 
scanning mutagenesis (PSM), a transposon incorporates 5 bp of target DNA, along with 5 
bp flanking both ends of the fragment just outside of a KpnI digest site.  This transposon 
is then incorporated into the gene, and the transposon fragment is removed through KpnI 
digestion, leaving the 5 bp fragment incorporated into the gene (120). 
Aside from transposons, the genetic sequence can be diversified through 
recombination methods.  These methods can include homologous recombination, such as 
DNA shuffling or random chimeragenesis on transient templates (RACHITT), or it can 
be through non-homologous recombination exemplified in the incremental truncation for 
the creation of hybrid enzymes (ITCHY, SCRATCHY) or degenerate oligonucleotide 
gene shuffling (DOGS) methods (120).  In methods such as error-prone PCR, mutations 
are incorporated randomly throughout the gene, which incorporates both beneficial and 
deleterious mutations.  Unlike in nature where sexual reproduction eliminates the 
deleterious mutations through parental crosses, these random incorporations can quickly 
lead to inactivated enzyme.  DNA shuffling is an in vitro method to more closely mimic 
natural DNA crosses and incorporate diversity based on beneficial mutagenesis (120).  
This diversity can be incorporated in two separate protocols for DNA shuffling – 
fragmentation based shuffling or synthetic gene shuffling. 
In fragmentation based shuffling, a pool of gene mutants or gene homologs is 
digested by DNase I and the fragments are gel extracted.  These fragments are often 
between 50 and 200 bp and should be long enough to ensure efficient homologous end 
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recombination but not so long that little or no diversity is shuffled into the gene.  The 
fragments are then used as primers in a primerless PCR reaction in order to reconstitute 
the entire gene fragment, which can then be amplified using forward and reverse primers 
at the end of the gene.  Several variations of this fragmentation based DNA shuffling 
method exist, often differentiated by how the fragments are created.  In nucleotide 
exchange and excision technology (NExT), the DNA is fragmented by incorporation of 
uridine (dUTP) during PCR of the gene, followed by digestion with uracildeglycosylase 
(UDG) and sodium hydroxide (120).  Fragmentation based DNA shuffling is a quick and 
efficient way to shuffle diversity into a gene.  By digesting a gene that has been randomly 
mutated, the shuffling technique will allow the sequence to vary based on the fragment 
length.  This method can also be used to shuffle several gene homologs together in order 
to incorporate the diversity seen throughout a gene family.  However, due to the need to 
use the fragments as a primer, there is a minimum homology requirement for the gene 
homologs. 
Synthetic gene shuffling improves upon fragmentation based shuffling in two 
ways.  Synthetic shuffling builds diversity into synthetic oligonucleotides, which allows 
the mutated sites to vary independent of one another.  Since the oligos are designed, this 
technique can accurately tune the level of mutagenesis to the desired amount.  Secondly, 
the oligonucleotides are built in order to anneal properly at their areas of overlap, so non-
overlapping areas are not constrained by a minimum required homology such as what is 
required for fragmentation based shuffling.  Synthetic shuffling was first developed by 
Stemmer et al. in 1995 where a complete gene was reassembled using multiple 
oligonucleotides (105).  In this case, the gene being reconstituted was a β-lactamase 
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encoding gene (bla) with a gene size of 1.1 kilobases (105).  This 1.1 kb gene was 
reassembled in a primer-less PCR reaction using 56 oligos, each of which were 40 
nucleotides in length (105).  Following the primer-less PCR reaction, two primers 
flanking the entire gene were added in a PCR reaction to amplify the entire gene 
fragment.  This product was then digested and ligated into a plasmid to transform into E. 
coli.  Based on clones that had ampicillin resistance, 76% of the reconstituted genes 
expressed fully active enzyme (105).  This report pointed out the potential utility of the 
gene shuffling method to incorporate mutations into a gene. 
Another report used a modified approach to combine both fragmentation and 
synthetic gene shuffling in order to improve glyphosate tolerance in plants (16).  Castle et 
al. discovered a gene capable of detoxifying glyphosate in Bacillus species (16).  
Glyphosate is toxic to plants because it inhibits the enolpyruvyl-shikimate-3-phosphate 
synthase (EPSPS) enzyme in plant chloroplasts, which effectively inhibits aromatic 
amino acid biosynthesis (16).  The Bacillus species were found to express N-
acetyltransferases capable of acetylating glyphosate to produce N-acetylglyphosate, 
which is non-herbicidal (16).  With this discovery came the realization that this enzyme 
efficiency (0.87 mM-1 min-1) was much too low to allow herbicide tolerance in plants.  To 
improve enzyme activity, the gene was shuffled with homologs that were 94% identical 
to the original glyphosate N-acetyltransferase (GAT) using fragmentation based 
shuffling.  After several rounds of fragmentation based shuffling, a handful of variants 
with higher acetyltransferase activity were found through screening the transformants, 
but improvements in enzyme activity had begun to level off.  In order to improve the 
GAT further and to introduce more diversity, synthetic gene shuffling was used to build 
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oligonucleotides that encapsulated the variation seen in GAT mutants as well as GAT 
homologs with as little as 59% sequence identity (16).  Along with synthetic gene 
shuffling, a robust selection method was used based on E. coli’s ability to grow on 
increasing amounts of glyphosate, which is toxic to wild-type E. coli strains.  After 11 
total iterations of gene shuffling, Castle’s group was able to isolate a variant with 8320 
mM-1 min-1 enzyme efficiency.  This constitutes a 10,000-fold increase over the wild-type 
and was enough to confer glyphosate resistance in plants (16). 
Large improvements in glyphosate N-acetyltransferase activity were seen due to 
the ability of synthetic gene shuffling to rapidly increase the sequence diversity.  In order 
to compare synthetic gene shuffling with fragmentation based protocols, Ness et al. 
calculated the potential library size generated by each of these method for a subtilisin 
gene (82).  Ness et al. indicates that the theoretical size of a synthetically shuffled library 
of subtilisin would be dependent on the product of the number of variations at each 
varied position (82).  Thus, in their gene shuffling experiments, 54 varied positions 
created 1018 possible combinations.  They also calculated the library size for a 
fragmentation based library and found that the possible size would be about 108 fold 
smaller or a library size of 1010 combinations (82).  These calculations highlight the 
utility of using synthetic gene shuffling to increase the sequence diversity, but Ness also 
points out some of the pitfalls.  One of the biggest concerns in synthetic shuffling is 
incorporating mutations that lead to a frame-shift mutation that renders the encoded 
protein inactive (131).  This problem can occur both during oligo synthesis as well as 
during the shuffling steps.  Oligo errors occur during synthesis due to the coupling 
efficiency, which is the chance of incorporating the desired nucleotide during each 
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successive round of oligonucleotide synthesis.  At each step, a small percentage of oligos 
will fail to incorporate a nucleotide due to several factors such as moisture since water 
can react with the incoming nucleotide to prevent its incorporation.  A 60-mer oligo 
product with a 99.5% coupling efficiency (which is commonly considered the best 
possible coupling efficiency available today) would contain about 74% full length 
product after synthesis.  Although many of these oligos will be missing one nucleotide at 
the end ( n-1), which will still incorporate properly into the reconstituted gene, several 
will be missing internal nucleotides, which if incorporated could lead to frameshift 
mutations.  The anticipated percentage of active enzyme variants is only about 1% (131), 
due to these frameshift mutations, which makes the development of an efficient selection 
system for active enzyme all the more important.    
The other homologous recombination method to highlight is the random 
chimeragenesis on transient templates (RACHITT) method.  Similar to fragmentation 
based shuffling where a library of random mutants or pool of homologous genes is 
fragmented by DNase I, the RACHITT method then uses a uracil-containing template 
strand to hybridize the fragments.  The gaps are then filled in using a Pfu polymerase and 
the uracil containing template is removed using uracil-DNA-glycosylase (120).  This 
process was seen in the molecular breeding of a dibenzothiophene monooxygenase used 
for the biodesulferization of fossil fuels (20).  The RACHITT method incorporated an 
average of 14 crossovers per gene (1.25 kb) and resulted in a 20-fold increase in enzyme 
activity (20). 
The homologous recombination methods highlighted above constrain the user 
based on gene homology.  Additionally, some theories hold that the gene can be broken 
34 
 
 
into distinct domains that make up building blocks of the protein.  Nonhomologous 
recombination allows the recombination of distinct gene fragments as well as the 
investigation into how gene units are responsible for enzyme activity (120).  A 
nonhomologous recombination technique is known as incremental truncation for the 
creation of hybrid enzymes (ITCHY) (120).  ITCHY allows nonhomologous templates to 
recombine by incrementally truncating the 5’ end from one gene and the 3’ end from 
another.  These two fragments are then ligated together to create chimeras with one 
crossover.  Although this method allows chimeras to be generated from nonhomologous 
templates, the gene length is not conserved.  This method is often combined with DNA 
shuffling in order to incorporate high numbers of crossover events and is known as 
SCRATCHY in those iterations (120).   
The ability to mutate a gene is not difficult, but to do it in a way that leads to the 
successful isolation of a desired variant can often be a complex task.  As is seen in the 
examples above, the generation of gene variants can be done using many different 
methods that often need to be tailored to the desired level of mutagenesis.  Once a gene 
library is built, a successful screen or selection must be developed to sample that 
diversity.  The method often depends on the size of the library.  For example, for small 
libraries, a simple colorimetric screen can be done for the isolation of improved variants.  
For larger libraries more high-throughput methods are needed, such as a biosensor or a 
growth selection.  These techniques are often tailored to the target reaction, and so will be 
discussed in more detail in the individual thesis chapters.  However, none of this 
evolution through rational design or directed enzyme evolution can begin until the target 
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gene is identified.  That gene for us codes for the enzyme mevalonate diphosphate 
decarboxylase. 
 
Mevalonate Decarboxylase 
Our target for biofuel and platform chemical production is mevalonate 
diphosphate decarboxylase, which we found to be capable of a non-native substrate 
reaction to produce isobutene (Chapter 3).  Understanding the enzyme structure and 
reaction mechanism can be critical in determining which strategy (rational design or 
directed enzyme evolution) to use for improving isobutene production.  This section of 
my thesis highlights our understanding of the conventional mevalonate disphosphate 
decarboxylase and also analyzes the proposed mevalonate monophosphate decarboxylase 
as a second target enzyme to produce isobutene. 
 
I. Mevalonate diphosphate decarboxylase 
Mevalonate diphosphate decarboxylase (MDD) is an essential enzyme in the 
mevalonate (MVA) pathway.  This pathway is found in many organisms such as fungi, 
plants, animals, some archaea, and some bacteria (79).  The MVA pathway is essential in 
these organisms due to the critical products that are produced.  Ultimately the pathway 
produces a diverse family of compounds known as isoprenoids, which is one of the 
largest and most diverse classes of compounds with 20,000 to 35,000 variants (22).  
These compounds are critical in membrane structure (cholesterol and squalene), defense 
and communication (terpenes), energy transfer (carotenoids), growth regulation 
(gibberellins), and many other metabolic processes (25).  The MVA pathway itself uses 
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acetyl-CoA to make isopentenyl diphosphate (IPP) and dimethylallyl pyrophosphate 
(DMAPP), which can then be used to make the vast array of isoprenoids listed above 
(Fig. 6).   
 
FIG. 6. The mevalonate (MVA) and methylerythritol phosphate (MEP) pathways.  The MVA 
pathway is composed of acetoacetyl-CoA thiolase (atoB), HMG-CoA synthase (HMGS), HMG-
CoA reductase (HMGR), mevalonate kinase (MK), mevalonate phosphate kinase (MVPK), 
mevalonate diphosphate decarboxylase (MDD).  The MEP pathway is composed of DOXP 
synthase (dxs), DOXP reductase (dxr/ispC), 4-diphosphocytidyl-2-methylerythritol synthase 
(ispD), 4-diphosphocytidyl-2-methylerythritol kinase (ispE), 2-methylerythritol 2,4-
cyclodiphosphate synthase (ispF), HMB-PP synthase (ispG), HMB-PP reductase (ispH/LytB).   
In the mevalonate monophosphate pathway, mevalonate monophosphate decarboxylase (MPD) 
and isopentenyl phosphate kinase (IPK) are used.  
 
Besides the MVA pathway, there is only one other known pathway to make the 
essential IPP and DMAPP intermediates: the deoxyxylulose phosphate pathway aka the 
methylerithritol phosphate (MEP) pathway (79).  This pathway is found in some bacteria, 
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such as E. coli, as well as some plants and eukaryotic parasites (79).  In the MEP 
pathway, glyceraldehyde-3-phosphate and pyruvate are used to make IPP and DMAPP 
(Fig. 6) (22).  The MEP pathway has also been looked at as a possible tool in limiting 
certain gram-positive bacteria from proliferating in humans, including the protozoan 
parasite that causes malaria (Plasmodium) (67, 79).  By inhibiting the DXP 
reductoisomerase (dxr) of the MEP pathway, which is essential to Plasmodium, certain 
antibiotics have shown promising preliminary results in reducing the incidence of malaria 
(67). 
Investigation of the MVA pathway has been a source of scientific interest for 
several years.  Besides the desire to understand an essential pathway present in many 
organisms, including humans, researchers have targeted MVA pathway enzymes as a 
way to reduce cholesterol production using drugs known as statins (33).  Additionally, 
more recent work has focused on the MVA pathway due to its defects related to human 
inherited diseases.  For example, mutations in the mevalonate kinase of the MVA 
pathway are linked to two diseases—mevalonic aciduria and Hyper-IgD syndrome (79).   
Although both the MVA and MEP pathways produce the essential metabolites 
IPP and DMAPP, there are some significant differences between the two.  The MVA 
pathway as a whole uses 1.5 glucose to produce IPP, 4 CO2, and 8 [H], whereas the MEP 
pathway uses one glucose along with three ATP and two [H] to produce IPP, CO2, and 
ADP.  In the first step of the MVA pathway two acetyl-CoA are condensed to form 
acetoacetyl-CoA, catalyzed by the acetoacetyl-CoA thiolase enzyme (79).  This reaction 
utilizes one acetyl-CoA and produces a free CoASH.  The next step in the pathway is 
catalyzed by HMG-CoA synthase and involves the condensation of acetyl-CoA with 
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acetoacetyl-CoA to form 3-hydroxy-3-methylglutaryl-CoA.  Next, HMG-CoA reductase 
takes (S)-HMG-CoA and through successive reductions produces (R)-mevalonate with 
the concomitant oxidation of 2 NADPH to NADP+ as well as the production of free 
CoASH.  (R)-mevalonate is then phosphorylated twice, first by mevalonate kinase (MK) 
and then by mevalonate phosphate kinase (MVPK), to produce mevalonate diphosphate 
with the use of ATP in each step.  In the final, and most critical step to our work, 
mevalonate diphosphate decarboxylase (MDD) is used to decarboxylate mevalonate 
diphosphate into isopentenyl diphosphate (IPP) with the evolution of CO2 (79).  IPP can 
then be converted to DMAPP via isopentenyl diphosphate isomerase (IDI).  From the 
critical IPP and DMAPP isomers, the isoprenoid chains are elongated into geranyl 
diphosphate (GPP), farnesyl diphosphate (FPP), and geranylgeranyl diphosphate (GGPP), 
which are then in turn used to create a vast array of isoprenoid products (25). 
The importance of the MDD catalyzed reaction to our research necessitates a 
deeper look into the enzyme’s structure/function.  For our work, the Saccharomyces 
cerevisiae enzyme (ScMDD) was used and so any reference to amino acid residues will 
refer to ScMDD (NCBI Accession #CAA66158) (13).  The MDD catalyzed reaction is an 
ATP dependent decarboxylation and dehydration of mevalonate diphosphate (MVAPP) 
into IPP (79) (Fig. 7) and this activity has been shown both in vivo and in vitro in several 
organisms including animals, plants, and yeast.  Other work demonstrated that the MDD 
reaction most likely occurs through a two-step mechanism, wherein the C3 hydroxyl 
group is phosphorylated, which enhances its leaving-group ability, and this 
phosphorylation is then followed by decarboxylation of the substrate (31).  Work done on 
the avian-derived enzyme was used to show that the phosphoryl transfer to the C3 oxygen 
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inverted the stereochemistry, which implies that no covalent enzyme phosphate 
intermediate is formed (52).  Understanding the reaction chemistry as well as critical 
active site residues is important for any strategy to improve enzyme activity, especially 
through rational design.    
 
FIG. 7. The reaction of mevalonate diphosphate decarboxylase (MDD) on its native substrate 
mevalonate diphosphate is initiated by the phosphorylation of the C3-hydroxyl group.  This step 
is coordinated by the Ser121 residue and procedes after the Asp302 acts as a general base.  This 
phosphorylation is followed by a dephosphorylation and spontaneous rearrangement to satisfy the 
carbocation intermediate, ultimately yielding isopentenyl diphosphate (IPP) as the product. 
 
Work by Bonanno et al. 2001 to crystallize the ScMDD has provided some 
insights into MDD’s structure and function.  Unfortunately, to this date, no structure has 
been solved with the substrate bound in the active site, and so much of the work done to 
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implicate residues in substrate binding and catalysis has been done using alternative 
methods.  Initial analysis of the ScMDD active site looked at residues that were 
conserved throughout many homologs of ScMDD and found that Lys-18 was conserved 
throughout the 20 sequences tested, and Asp-302 was strictly conserved in 25 sequences 
analyzed (60).  When the Asp-302 residue was mutated to alanine, the catalytic activity 
saw a 105 decrease (79).  Based on further alanine substitution studies, several serine 
residues were implicated in catalysis, ATP, or substrate interactions.  Ser-121 mutated to 
alanine had a large effect (104 fold decrease) in the catalytic activity of the enzyme.  The 
close distance between Ser121 and mevalonate diphosphate indicates that they are within 
hydrogen bond forming distance, and this interaction is hypothesized to help orient the 
substrate in the active site (124).  Also, Ser-153 was found to have a possible interaction 
with ATP and Ser-155 with the MVAPP substrate binding.  Simulation-based studies 
indicated that Ser-155 is within hydrogen bond distance from the MVAPP substrate 
(124), and this implied interaction is backed up by mutagenesis data indicating that a Ser-
155 mutation to alanine results in a 16-fold increase in Km for MVAPP (60). 
Molecular docking and simulation-based studies have backed up the function 
work, indicating that Asp-302 is less than 4 Å and is the catalytically important residue 
that interacts with the C3 hydroxyl group (124).  Additionally, substrate modeling 
indicated that an Arg-74 interacted with the second phosphate in the diphosphate moiety 
of mevalonate diphosphate (79).  And for the C1 carboxyl head-group of mevalonate 
disphosphate, modeling indicates that a Tyr-19 residue is involved in the interaction 
(124).  Ala-15 and Lys-22 were also indicated to interact with MVAPP and ATP, 
respectively (124).  With this structure and function data in mind, we had a better 
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understanding of how to attempt to improve the enzyme’s activity.  However, if there 
were an enzyme that had already evolved the ability to decarboxylate and dehydrate a 
substrate more similar to 3-HMB, that might be an advantage, and that is what led us to 
pursue a mevalonate monophosphate decarboxylase. 
 
II. Putative mevalonate monophosphate decarboxylase (MPD) 
In our studies, we show that the MDD enzyme, which has native substrate 
specificity for mevalonate diphosphate, can be used to decarboxylate the alternative 
substrate 3-HMB to form isobutene.  The alternative substrate mimics the native substrate 
except that 3-HMB is missing the diphosphate moiety as well as a methylene group.  The 
identification of a decarboxylase variant whose substrate specificity may be for an 
intermediate substrate, such as mevalonate monophosphate, would be of great interest to 
us as a way to see if a step-wise evolutionary approach to changing substrate specificity 
could yield enzymes with higher isobutene-forming capability.  For this reason, reports of 
a proposed mevalonate monophosphate decarboxylase step in an alternative MVA 
pathway prompted us to look more closely into this possibility. 
Archaea utilize large amounts of isoprenoids for the production of lipids such as 
those used for cell membrane formation (79).  Their importance is enhanced due to the 
fact that archaea utilize isoprenoids for synthesis of ether-linked membrane lipids, as 
opposed to the typical ester-linked fatty acid derived lipids seen in bacteria and 
eukaryotes (76).  So it comes as a surprise that in most archaea there is no known 
mevalonate phosphate kinase (MVPK) or mevalonate diphosphate decarboxylase (MDD) 
present.  It was also found in in vitro studies that Methanocaldococcus jannaschii has an 
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isopentenyl phosphate kinase (IPK) capable of phosphorylating isopentenyl phosphate to 
isopentenyl diphosphate (IPP) (79).  This activity, coupled with IPK’s inability to 
phosphorylate mevalonate phosphate led to the prediction of an alternative mevalonate 
pathway in archaea.  In this alternative pathway, mevalonate phosphate is decarboxylated 
and dehydrated to isopentenyl phosphate via a mevalonate monophosphate decarboxylase 
(Fig. 6).  This isopentenyl phosphate product would then be phosphorylated via IPK to 
isopentenyl diphosphate in order to form the two key intermediates IPP and DMAPP 
(79).  X-ray crystal structure of some heterologously expressed IPKs have shown 
isopentenyl phosphate and ATP binding in the active site, or IPP and ADP binding in the 
active site, which adds to the evidence for IPK’s function (79). 
At this point even though extensive work has been done on the subject, no 
mevalonate monophosphate decarboxylase have been discovered or characterized (79).  
Based on evolutionary and phylogenetic analysis, there appears to be strong evidence to 
support an alternative MVA pathway that contains a mevalonate monophosphate 
decarboxylase (76).  The discovery of this will not only advance the understanding of 
how the distinct isoprenoid biosynthesis pathways came about, it could also offer a prime 
target to study for isobutene-forming activity. 
Although our targeted use of mevalonate diphosphate decarboxylase and its 
variants is for isobutene production, several groups have worked on using the isoprenoid 
biosynthetic pathway for fuels production (85).  The interest in using the isoprenoid 
pathway is due to the potential to produce many different types of hydrocarbons.  
Gasoline substitutes could be produced from branched, short chain terpenes or alcohols, 
and longer chain cyclic or branched terpenes could be used for diesel or jet fuel (85).  The 
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utility of using the isoprenoid biosynthetic pathway for fuels production has been 
demonstrated by the production of farnesene at 14 g/L in E. coli (91).  Farnesene can be 
hydrogenated to farnesane, which has a high cetane number suitable for diesel fuel (85, 
95).  Additionally, several terpene compounds such as pinene, sabinene, and terpinene are 
being analyzed for their use as jet fuel replacement compounds (85).   
Aside from natural isoprenoid pathway products being used as fuel replacements, 
some work has been done to engineer the pathway to divert carbon to isopentenol or 
isopentanol.  Currently, isopentanol has been produced through the successive 
dephosphorylation of IPP (85).  Isopentanol is a biofuel target because of its high energy 
density.  First, the gene needed to convert IPP into isopentenol was found in Bacillus 
subtilis by screening a cDNA library to find genes capable of relieving prenyl-
diphosphate toxicity in E. coli (85, 127).  The screen led to the discovery of nudF, which 
relieves toxicity in E. coli and converts IPP and DMAPP into isopentenol at 1.2 g/L (85, 
127).  Another method involves the decarboxylation and dehydration of mevalonate into 
isopentenol, with conversion to isopentanol (73).   
In this thesis I will identify the enzyme (MDD) that we used to produce isobutene.  
Additionally discussed are the methods used to improve the enzyme activity to produce 
isobutene, including the development of two methods to select for improved variants.  
With the methods reviewed in this chapter in mind, we developed techniques to identify 
and develop MDD’s ability to produce the valuable platform chemical and fuel molecule 
isobutene. 
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Chapter 3. Formation of Isobutene from 3-hydroxy-3-methylbutyrate 
by Diphosphomevalonate Decarboxylase 
 
A paper published in the journal  
Applied and Environmental Microbiology 
 
David S. Gogerty and Thomas A. Bobik 
Abstract 
Isobutene is an important commercial chemical used for the synthesis of butyl 
rubber, terephthalic acid, specialty chemicals, and a gasoline performance additive 
known as alkylate.  Currently, isobutene is produced from petroleum and hence is 
nonrenewable.  Here we report that the Saccharomyces cerevisiae mevalonate 
diphosphate decarboxylase (ScMDD) can convert 3-hydroxy-3-methylbutyrate (3-HMB) 
to isobutene.  Whole cells of Escherichia coli producing ScMDD with an N-terminal 6 x 
His tag (His6-ScMDD) formed isobutene from 3-HMB at a rate of 154 pmol h-1 g cells-1.  
In contrast, no isobutene was detected from control cells lacking ScMDD.  His6-ScMDD 
was purified by nickel affinity chromatography and shown to produce isobutene from 3-
HMB at a rate of 1.33 pmol min-1 mg-1 protein.  Controls showed that both His6-ScMDD 
and 3-HMB were required for detectable isobutene formation.  Isobutene was identified 
by gas chromatography (GC) with flame ionization detection as well as by GC-mass 
spectrometry (MS).  ScMDD was subjected to error-prone PCR, and two improved 
variants were characterized, ScMDD1 (I145F) and ScMDD2 (R74H).  Whole cells of E. 
45 
 
 
coli producing ScMDD1 and ScMDD2 produced isobutene from 3-HMB at rates of 3000 
and 5888 pmol h-1 g cells-1, which are 19- and 38-fold increases compared to rates for 
cells producing His6-ScMDD.  This showed that genetic modifications can be used to 
increase the rate at which ScMDD converts 3-HMB to isobutene.  Because 3-HMB can 
be produced from L-leucine, ScMDD has a potential application for the production of 
renewable isobutene.  Moreover, isobutene is a gas, which might simplify its purification 
from fermentation medium, substantially reducing production costs.  
 
Introduction 
The United States consumed about 360 billion gallons of petroleum products in 
2008 while domestically producing only 76 billion gallons (116, 117).  The U.S. Census 
Bureau estimates that these imports cost the United States about $252 billion (115).  
Petroleum is critical for the production of transportation fuels as well as a variety of 
consumer products, including plastics, medicines, and fertilizers.  However, petroleum is 
nonrenewable, a source of greenhouse gasses when burned, and a national security issue.  
Hence, renewable petroleum replacements are a national priority.  Biofuels, such as 
ethanol, have displaced some of our gasoline needs, reducing our dependence on foreign 
oil as well as benefiting our environment (70).  However, ethanol has a lower energy 
density than gasoline, which increases distribution costs, and it is not fully compatible 
with existing pipelines and engines (1, 3, 27, 95).  Longer-chain alcohols and biological 
hydrocarbons are promising second-generation biofuels with improved characteristics 
compared to bioethanol, but the technology needed to produce such fuels economically is 
currently unavailable (1, 3, 27, 95).  Accordingly, intensive research is underway to 
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improve the production of second-generation biofuels and identify new renewable fuel 
molecules.  
Isobutene is an interesting molecule for the production of renewable fuels and 
chemicals.  Isobutene is a product of petroleum refining that is used for the production of 
butyl rubber, specialty chemicals, and a gasoline additive known as alkylate (54, 72, 97).  
Gasoline alkylate is produced by polymerization of a mixture alkanes and alkenes (such 
as isobutene) and is usually blended with gasoline at a level of 10 to 15% (72).  Alkylate 
increases octane, improves combustion, reduces tailpipe emissions, and prevents engine 
knock.  Isobutene can also be dimerized and hydrogenated to isooctane, a promising 
replacement for the gasoline oxygenate methyl tertiary-butyl ether, which is an 
environmental concern (72).  Moreover, isooctane could serve as a direct gasoline 
replacement that has a high energy density and is fully compatible with the existing 
infrastructure, although it would need to be blended with a minor fraction of butane to 
increase vapor pressure for cold-weather starting.  
A major challenge to commercial production of renewable isobutene is that an 
efficient biological pathway for its formation is unavailable.  Prior studies showed that a 
microsome-associated cytochrome, P450rm, from Rhodotorula produced isobutene from 
isovalerate at a rate of 4.8 nmol min-1 mg-1 (45).  However, this rate is too low for 
commercial application, and to our knowledge no genetic improvements have been 
reported for P450rm in the 13 years since its encoding gene was identified (42).  Such 
studies may have been hampered by the fact that P450rm is a poorly understood 
membrane-associated protein that is difficult to produce in heterologous hosts (102).  
Consequently, the identification of alternative isobutene-forming enzyme(s) will likely be 
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crucial for the production of renewable isobutene.  In this report, we show that 
mevalonate diphosphate decarboxylase from Saccharomyces cerevisiae (ScMDD) can 
convert 3-hydroxy-3-methylbutyrate (3-HMB) to isobutene.  
 
Materials and Methods 
 
Bacterial strains and growth media.  The bacterial strains and plasmids used in 
the study are shown in Table 2.  Escherichia coli was cultured in lysogeny broth (LB) 
(Difco, Detroit, MI) at 37°C (5, 6).  Kanamycin was used at 50 µg/ml when necessary.   
 
Table 2.  Bacterial strains and plasmids used in this study. 
Strains Description Source 
BL21(DE3) F- ompT hsdSB(rB- mB-) gal dcm (DE3) New England 
Biolabs 
DH5α λ ‒ φ80dlacZ∆M15 fhuA2 ∆(lacZYA-argF)U169 
recA1 endA1 hsdR17(rK- mK+) phoA glnV44 thi-1 
gyrA96 relA1 
New England 
Biolabs 
DH10β araD139 ∆(ara,leu)7697 fhuA lacX74 galK 
(φ80lacZ∆M15) mcrA galU recA1 endA1 nupG rpsL 
(StrR)∆(mrr-hsdRMS-mcrBC) 
New England 
Biolabs 
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Table 2. (continued) 
DG25 DH5α with pUC57-ScMDD This study 
DG26 DH5α with pTA925-ScMDD This study 
DG29 BL21(DE3) with pTA925 This study 
DG30 BL21(DE3) with pTA925-ScMDD This study 
DG62 BL21(DE3) with pTA925-ScMDD with an I145F 
mutation  (ScMVDC1) 
This study 
DG63 BL21(DE3) with pTA925-ScMDD with an R74H 
mutation  (ScMVDC2) 
This study 
Plasmids   
pUC57 Ampr; pUC19 derivative GenScript 
pET41a Kmr; T7 expression vector Novagen 
pTA925  Kmr, pET41a derivative with a 5’ BglII cloning site (55) 
 
Chemicals and reagents.  Antibiotics were from Sigma Chemical Company (St. 
Louis, MO).  Isopropyl-β-D-thiogalactopyranoside (IPTG) was from Diagnostic 
Chemicals Limited (Charlotteville PEI, Canada).  Restriction enzymes and T4 DNA 
ligase were from New England Biolabs (Beverly, MA).  Ethidium bromide, 2-
mercaptoethanol, and SDS were from Bio-Rad (Hercules, CA).  Other chemicals were 
from Fisher Scientific (Pittsburgh, PA). 
Construction of E. coli strains for production of ScMDD.  The ScMDD gene 
(ERG19) was synthesized by GenScript optimized for protein production in E. coli with 
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an N-terminal His6 tag and flanking BglII and HindIII sites.  The synthetic ScMDD gene 
was excised from pUC57 using BglII and HindIII, isolated by agarose gel electrophoresis 
(96), and purified using a Qiagen QIAquick kit according to the manufacturer’s 
instructions.  The gene was ligated into T7 expression vector pTA925 (55) BglII to 
HindIII using T4 DNA ligase (New England Biolabs).  The ligation mixture was used to 
transform E. coli DH5α by electroporation with a Bio-Rad gene pulser as previously 
described (7).  The pTA925-His6-ScMDD DNA was isolated using a Qiagen miniprep kit 
and electroporated into E. coli BL21 (DE3) for protein production.  The synthetic 
ScMDD gene sequence was confirmed by DNA sequencing.   
Whole-cell assay for isobutene production.  About 300 ml of LB medium was 
inoculated with 1 ml of an overnight culture and incubated at 37°C until the optical 
density at 600 nm (OD600) reached 1.2 (about 5 h).  Then, protein production was induced 
with 1 mM IPTG for 17 h at 28°C, and cells were harvested using a Beckman Coulter 
Avanti J-25 centrifuge at 10,000 x g for 5 min.  Harvested cells were resuspended in LB 
broth to a concentration of 0.3 g ml-1, and 1 ml of cells was added to 1 ml of LB medium 
containing 50 µg/ml kanamycin, 1 mM IPTG, and 3-HMB as indicated in the text.  Assay 
components were combined in 10-ml glass gas chromatography (GC) vials that had screw 
caps with polytetrafluoroethylene (PTFE) (Teflon) inserts from Supelco (Bellefonte, PA).  
Vials were incubated at 37°C for the time specified in the text.  The vial headspace was 
sampled with a gas-tight syringe and analyzed for isobutene by gas chromatography with 
a flame ionization detector (GC-FID) or gas chromatography with mass spectrometry 
(GC-MS) as described below.  
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Purification of His6-ScMDD and variants for in vitro enzyme assays.  About 
300 ml of LB medium was inoculated with 1 ml of an overnight culture and incubated at 
37°C until the OD600 reached 1.2.  Protein production was induced with 1 mM IPTG for 
17 h at 28°C.  Cells were pelleted by centrifugation and washed twice with 20 mM Tris-
HCl, pH 7.0, containing 300 mM NaCl and 0.5 mM dithiothreitol (DTT).  Washed cells 
were resuspended in 10 ml B-PER II reagent along with 1 mg DNase I, 40 mM 
Calbiochem protease inhibitor cocktail set I, and 3 mM β-mercaptoethanol.  
Subsequently, a B-PER His tag purification kit (Thermo Scientific) was used for Ni 
affinity purification with all manipulations carried out inside an anaerobic chamber (Coy 
Laboratories) containing an atmosphere of 5% CO2, 5% hydrogen, and 90% nitrogen.  
Protein concentrations were determined using Bio-Rad’s protein assay reagent.  Purified 
enzymes were stored in sealed serum vials under an N2 atmosphere at 4°C.  The 
purification was evaluated by SDS-PAGE using 10 to 20% acrylamide Bio-Rad Ready 
gels and Bio-Rad Mini-Protean II electrophoresis cells according to the manufacturer’s 
instructions.  Gels were stained with Bio-Safe Coomassie (Bio-Rad).  
Enzyme assays for isobutene production.  Purified ScMDD and variants were 
added to 75 mM potassium-phosphate buffer, pH 7.4, with 5 mM magnesium chloride, 
20 mM potassium chloride, and ATP and β-HMB in varying amounts.  Assays were 
initiated by adding enzyme to assay mixtures in 4-ml vials while using anaerobic 
precautions.  The headspace of assay mixtures was sampled and analyzed by GC-FID. 
Isobutene analysis by gas chromatography.  Isobutene was measured by using 
a Varian 450GC with a CP-Sil 5 CB column fitted with a flame ionization detector.  The 
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method used a 10:1 split ratio and a 30-ml/min flow rate with helium as the carrier gas.  
The oven was held at 30°C for 3 minutes, which was the duration of the method.  
Isobutene analysis by GC-MS.  For confirmation of the isobutene peaks 
observed during GC-FID screening, an Alliant GC-mass spectrophotometer was used 
coupled with an Alliant HP-Plot/Q column composed of a polystyrene-divinylbenzene 
solid phase for monitoring very small chain hydrocarbons.  A linear velocity of 40 cm/s 
was used with a split ratio of 5:1 and a temperature program that held at 40°C for 1 min 
followed by a ramp at 10°C/min to 200°C. 
Random PCR Mutagenesis.  ScMDD was subjected to random mutagenesis 
using Clontech’s PCR mutagenesis kit and primers ScMVDC-F 
(GCCGCCAGATCTATGCATCATCATCATCATCATATGACCGT) and ScMVDC-R 
(GCCGCCAAGCTTACTCTTTCGGCAGGCCGGTTTT).  DNA amplified under 
mutagenic conditions was digested with BglII and HindIII and then gel purified using a 
Qiagen Qiaquick kit.  Next, the purified DNA was ligated into the T7 expression plasmid 
pTA925 by using T4 DNA ligase and transformed into E. coli BL21(DE3) RIL by 
electroporation.  Transformation mixtures were diluted to obtain about 100 transformants 
per plate.  In some cases, pure cultures were made from selected transformants.  
Alternatively, plates were then replica printed to two LB kanamycin plates.  Then, 
transformants were pooled by adding 2 ml of LB to the plate and using a spreader to 
suspend the colonies.  The pooled transformants (1 ml) were assayed for isobutene 
production.  
 
  
Results 
 
Isobutene production from 3
ScMDD.  Renewable isobutene has substantial commercial potential. 
tested ScMDD to determine whether it could convert 3
substrate) to isobutene (Fig. 8
FIG. 8. Reactions catalyzed by 
diphosphomevalonate to CO2 and isopentenyl 
In the report, we show that MDD also converts 3
product of leucine degradation. 
position, which is thought to leave as the phosphate dianion during decarboxylation.
 
E. coli strain DG30 was constructed for high
N-terminal 6xHis tag (His6-Sc
weight) was assayed for isobutene production by GC
formed isobutene at a rate of 155 ± 19 pmol h
detectable isobutene was formed when cells were omitted fro
cells of the negative control (strain DG29) were used. 
that it contains the expression plasmid without 
detected when 3-HMB was omitted from assays. 
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identified and quantified based on GC retention time and peak area compared to an 
authentic isobutene standard.  These results suggested that ScMDD converts 3-HMB to 
isobutene. 
Mutagenesis of ScMDD for enhanced isobutene production.  The His6-
ScMDD gene was mutagenized by error-prone PCR, ligated into the T7 expression 
plasmid pTA925, and transformed into E. coli BL21(DE3) RIL.  Individual transformants 
(4,000) along with 200 pools, each of which contained about 100 independent 
transformants (20,000 transformants total), were also tested for isobutene production by 
the whole-cell assay (see Material and Methods for a description of how the pools were 
made).  About 20 of these 200 pools showed increased isobutene production.  In these 
cases, the transformants used to make the pools were retested for isobutene production 
individually.  From the above studies, 21 mutants were identified that showed increased 
isobutene production in the whole-cell assay compared to that of E. coli producing wild-
type ScMDD.  Of the 21 mutants identified above, two (strains DG62 and DG63) were 
selected for further study.  DG62 and DG63 produced about 18-fold and 38-fold more 
isobutene than DG30 (produces wild-type ScMDD) in our whole-cell assay using GC-
FID detection (Table 3).   The His6-ScMDD variants produced by DG62 and DG63 were 
named His6-ScMDD1 and His6-ScMDD2, respectively.  DNA sequence analysis showed 
that His6-ScMDD1 and His6-ScMDD2 had single amino acid changes (I145F and R74H, 
respectively).  Controls showed that ScMDD and 3-HMB were required for isobutene 
formation by whole cells. 
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Strain/condition Amt of isobutene 
produced (pmol h-1 
g cells-1) 
No cells ND 
DG29 (no insert) ND 
DG30 (wild-type 
ScMDD) 
154 
DG62 (ScMDD1) 
(I145F) 
3000 
DG63 (ScMDD2) 
(R74H) 
5888 
 
TABLE 3: Isobutene production by whole cells producing ScMDD and variants as measured by 
GC-FID.  Assays were performed as described in Materials and Methods and contained 
approximately 0.3 g of induced whole cells and 10 mM 3-HMB.  No isobutene was detected 
without 3-HMB or cells producing ScMDD.  ND, none detected. 
 
Verification of isobutene formation by GC-MS.  Isobutene formation by whole 
cells of DG63 was verified by GC-MS.  About 0.3 g of DG63 cells (wet weight) was 
incubated together with 3-HMB in a sealed GC vial for 40 min.  Then, 100 µl of the 
headspace was analyzed by GC-MS (Fig. 9).  The total ion chromatogram (TIC) showed 
a peak at 11.61 minutes that matched the retention time of the isobutene standard.  The 
  
mass chromatograms for ions diagnostic of isobutene (56.07 and 41.04 m/z) (
indicated that isobutene was present in
DG63.  
FIG. 9. GC-MS of isobutene produced by whole cells of 
The top panel shows the total ion chromatogram obtained from assays of isobutene production by 
whole cells of DG63.  In this method, isobutene had a retention time of about 11.61 min. 
inset is a close-up of the isobutene peak. 
CO2, respectively.  The two smaller figures below are mass chromatograms obtained by 
monitoring the ions characteristic of isobutene (
 
In addition, the mass spectrum of the peak at 11.61 minutes was u
National Institute of Standards and Technology L
match to spectra for isobutene (2
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ScMDD variant R74H (strain DG63).
 The peaks at 1.81 and 2.57 min in the TIC are air and 
m/z 56.07 and 41.03).   
sed to query the 
ibrary.  Results showed a near
-methylpropene) (Fig. 10).  
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FIG. 10. Comparison of the MS spectrum for isobutene produced by ScMDD to library 
standards.  The top trace is the spectrum of the isobutene peak found in the headspace of assays 
containing DG63 whole cells, which produces ScMDD R74H.  This spectrum was used to search 
the National Institute of Standards and Technology Library, and a near-perfect match to isobutene 
standards was found (bottom trace). 
  
No isobutene peak was detected in assay mixtures containing control cells 
(DG29-pTA925-no insert) or in assay mixtures that lacked enzyme or 3-HMB.  
Cumulatively, these results confirmed that isobutene was formed in assay mixtures 
containing cells that produce His6-ScMDD2 (DG63).   
Purification of His6-ScMDD and His6-ScMDD2.  His6-ScMDD (wild-type) and 
His6-ScMDD2 (R74H, the most active variant) were purified from DG30 and DG63 by 
nickel affinity chromatography under anaerobic conditions.  Based on sodium SDS-
PAGE, we estimate that His6-ScMDD and His6-ScMDD2 were 90 to 95% homogenous 
(Fig. 11).  ScMDD is the band near 44 kDa.  The yields of purified protein from the 300-
ml LB culture were 18.1 and 6.7 mg, respectively, for His6-ScMDD and His6-ScMDD2.  
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FIG. 11. SDS-PAGE analysis of His6-ScMDD purification.  Lane 1, molecular mass markers; 
lanes 2 and 3, soluble crude extracts of ScMDD (wild-type) and ScMDD2 (R74H), respectively; 
lanes 4 and 5, ScMDD and ScMDD2 following purification by Ni-nitrilotriacetic acid (NTA) 
chromatography.  Lanes 2 to 5 contain 2 µg of protein each, and the gel was stained with 
Coomassie blue. 
 
  Isobutene production by purified His6-ScMDD and His6-ScMDD2.  To test 
whether purified His6-ScMDD and His6-ScMDD2 converted 3-HMB to isobutene, assays 
were carried out in sealed vials, and the headspace was analyzed by GC-FID.  Results 
showed that His6-ScMDD and His6-ScMDD2 produced isobutene at rates of 1.33 ± 0.27 
and 6.44 ± 0.95 pmol min-1 mg-1 protein, respectively (Table 4).  Controls showed that 
detectable isobutene formation required ScMDD, 3-HMB, and ATP as expected (Table 
4).  
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Amt of Isobutene (pmol min-1 
mg protein-1) produced by: 
Assay 
component 
His6-ScMDD His6-ScMDD2 
 Complete 1.33 ± 0.27 6.44 ± 0.95 
 ‒ATP ND ND 
 ‒3-HMB ND ND 
Boiled    
enzyme 
ND ND 
 
TABLE 4. Reaction requirements for isobutene formation by purified His6-ScMDD and His6-
ScMDD2.  aThe complete assay contained 500 µg ScMDD, 333 mM 3-HMB, 250 mM ATP, and 
standard assay components.  No isobutene was detected when ATP or 3-HMB was omitted 
(‒ATP and ‒3-HMB) from assay mixtures or when boiled enzyme was used in places of 
purified ScMDD.  ND, none detected. 
 
The use of anaerobic procedures gave consistently higher levels of activity, 
possibly due to protection of an oxygen-sensitive thiol group of the enzyme.  When 
enzyme assay mixtures were incubated for longer periods of time, trace amounts of 
isobutene were produced in negative controls due to chemical reactions as expected (87), 
but these amounts were much lower than the isobutene produced enzymatically.  In 
addition, GC-MS was used to verify that isobutene was produced by purified His6-
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ScMDD and His6-ScMDD2.  The mass chromatograms obtained had ions diagnostic of 
isobutene (56.07 and 41.04 m/z) at the expected retention time.  
In the enzyme assays described above, ScMDD2 formed isobutene at a rate 4.8-
fold higher than the wild-type enzyme (ScMDD).  This is substantially less than the 38-
fold increase in isobutene production observed for whole cells expressing ScMDD2 
compared to isobutene production observed for cells expressing ScMDD.  This was most 
likely due to instability resulting from the R74H mutation, since unlike the wild-type 
enzyme, some ScMDD2 precipitated when assays were heated to 37°C.  
Structural mapping.  The mutations found in ScMDD1 and ScMDD2 were 
mapped onto the three-dimensional structure of wild-type ScMDD (Fig. 12).  ScMDD1 
and ScMDD2 have mutations that map within or close to the proposed active site (119).  
The I145F mutation in ScMDD1 is positioned close to the active site, near serine 153, 
which was shown through mutational analysis to be an important contributor in binding 
and positioning the Mg-ATP complex that serves as a reaction substrate (49, 61, 124).  
The arginine 74 that is changed in ScMDD2 (R74H) is on the surface of the active site 
and is thought to contact the phosphate tail of the native substrate, diphosphomevalonate 
(119).  Based on these analyses, we infer that the I145F and R74H mutations alter the 
active site configuration, thereby improving enzymatic activity with 3-HMB.  
 
  
FIG. 12. Structural mapping of 
of the ScMDD monomer, and the right side is an expanded view of the active site.  Residues 
proposed to be part of the active site are red or blue, with blue indicating a mutation that 
increased the rate of isobutene formation from 3
isobutene 38 times faster than wild
to form the bottom edge of the active site and interact with the pyrophosphate group of the 
substrate.  Variant ScMDD1, which produces isobutene 18 times fas
I145F mutation.  Although not within the active site, the residue occurs within a helix important 
for ATP binding and could affect the active site structure. 
Protein Data Bank (PDB) accession n
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various organisms (74).  MDD is now one of two enzymes known to produce isobutene.  
The other is a cytochrome, P450rm, from Rhodotorula minuta (45).  Both enzymes 
produce isobutene from products of leucine degradation and hence have potential 
application to the production of renewable isobutene.  
Importantly, the biological production of isobutene might minimize two major 
costs typically associated with the production of biofuels and green chemicals.  A number 
of renewable chemicals (1-butanol is a notable example) are toxic to producer organisms 
and inhibit their growth at relatively low concentrations (133).  This reduces yield, which 
dramatically raises product recovery costs.  Because isobutene is a gas, it may be 
relatively simple to pipe it away from the fermentation vessel as it is formed, minimizing 
toxicity.  In addition, gas-phase removal may provide a simple method for the separation 
of isobutene from the fermentation where it is produced, which can be a major cost in the 
production of renewable chemicals (53, 95, 133).  In the case of bioethanol, distillation 
accounts for about 9% of its total cost and 58% of the total energy use at an ethanol plant 
(71), and distillation of 1-butanol would be more expensive due to its higher heat of 
vaporization (95).  Thus, isobutene produced from renewable feedstocks has significant 
potential for the production of renewable chemicals and second-generation biofuels at 
lower cost. 
In terms of theoretical yields and energy requirements, the production of 
isobutene from glucose appears to be competitive with other biofuels.  The production of 
one isobutene and two CO2 molecules from one glucose preserves 90% of the heat of 
combustion of glucose, is redox balanced, and ATP generating (if produced via the 
metabolic pathway discussed below).  When glucose is converted to two ethanol 
62 
 
 
molecules or one butanol molecule (and CO2), the enthalpies of combustion yield are 
97% and 95%, respectively, and both processes are redox balanced and ATP generating.  
Thus, for biofuels applications, isobutene is at a disadvantage compared to ethanol and 1-
butanol in terms of energy yield (and polymerization costs).  However, these costs might 
be more than offset by the higher energy density of alkylate (about 48 MJ/kg), its 
compatibility with existing infrastructure, and the possibility that a gas may be less 
expensive to purify from fermentation medium.  Thus, overall, isobutene appears to have 
significant potential as a renewable chemical. 
Presently, there are two main challenges to the commercial production of 
renewable isobutene from 3-HMB using the ScMDD enzyme described in this report.  
First, although biological production of 3-HMB is possible via leucine degradation, the E. 
coli pathway of leucine biosynthesis is unsuitable.  E. coli synthesizes leucine from two 
molecules of pyruvate plus one molecule of acetyl coenzyme A (acetyl-CoA).  This 
pathway would convert 1.5 molecules of glucose to one isobutene molecule, five CO2 
molecules, and 5 excess reducing equivalents.  There is no straightforward way of 
recapturing the reducing equivalents formed; reaction with molecular oxygen to form 
water would substantially reduce the enthalpy of combustion yield, which would raise 
feedstock (glucose) costs to prohibitive levels with respect to biofuels applications.  
However, there are some promising alternatives.  One possibility is to produce 3-HMB in 
a homoacetogen.  These organisms can produce two ATP and three acetyl-CoA 
molecules from one glucose molecule (35).  A pathway that converts three acetyl-CoA 
molecules to methylcrotonyl-CoA and has been proposed in Myxococcus (8), and studies 
of Galactomyces have identified a route for the conversion of methylcrotonyl-CoA to 3-
  
HMB (30).  The combination of 
potentially provides a redox-balanced pathway from glucose to isobutene via 3
would have a high theoretical enthalpy 
this pathway into a homoacetogen 
genetic systems are not as advanced in the homoacetogens as they are in other bacteria 
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Lastly, it might also be possible to engineer isobutene production into a photosynthetic 
organism where carbon and energy are derived by CO2 fixation and sunlight rather than 
organic feedstocks such as glucose, which are the major production cost. 
A second challenge to the production of renewable isobutene is the development 
of an enzyme that produces isobutene at a high rate.  The rates of isobutene formation by 
ScMDD (described here) and P450rm of Rhodotorula (45) are 1.33 pmol min-1 mg-1 and 
4.8 nmol min-1 mg-1, respectively.  These levels of activity are too low for commercial 
application, but genetic improvements may be possible.  In the case of ScMDD, the 
highest rate of isobutene formation observed for whole cells was 5,888 pmol h-1 g cells-1 
(0.33 µg h-1 g cells-1).  We estimate that this level of activity is about 106-fold below the 
activity needed for a commercial process (2 to 4 g L-1 h-1 of product is needed).  
However, we have shown that the activity of ScMDD with 3-HMB can be improved 
genetically, and in recent years excellent progress has been made in directed enzyme 
evolution (92, 94, 108).  For example, the activity of glyphosate acetyltransferase was 
increased about 10,000–fold (16, 103).  Moreover, if ScMDD could be engineered to 
have the same activity with 3-HMB as with its native substrate (about 6 µmol min-1 mg-
1), that would be sufficient for commercial application (60).  This suggests that the 
needed level of increase is possible.  Importantly, ScMDD offers the opportunity for 
directed evolution of an isobutene-forming enzyme in a host (E. coli) that is highly 
amenable to sophisticated genetic manipulations.  This will substantially facilitate the 
development of high-throughput screens and selections crucial for directed enzyme 
evolution.  Thus, the production of renewable isobutene via ScMDD is a possibility, and 
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because of the advantages inherent in the chemical nature of isobutene, we think it has 
the potential to transform the biofuels industry. 
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Chapter 4. Mevalonate Growth Selection 
 
Abstract 
Here we describe the development of an E. coli strain dependent on isopentenol 
for growth in order to select for MDD variants with enhanced isobutene-forming activity.  
The selection relies on the production of isopentenol from mevalonate, a substrate that 
physically more closely resembles our 3-HMB target molecule than MDD’s native 
substrate mevalonate diphosphate.  We hypothesize that enhancing MDD’s ability to 
decarboxylate mevalonate will also increase the rate of isobutene formation in what 
amounts to a ‘step-wise’ approach to directed enzyme evolution.  Although the isolation 
of variants with improved mevalonate decarboxylase activity will not necessarily be 
mutants with higher 3-HMB decarboxylase activity, this method offers the closest in vivo 
selection method to the target reaction.  No variants have been found that grow 
exclusively on mevalonate indicating that multiple mutations will be needed for such 
growth.  Tests to reduce the stringency of the selection by adding small amounts of 
isopentenol led to the isolation of several mutants with higher mevalonate decarboxylase 
activity.  The best performing mutant, MS-Sc-1, had isopentenol-forming activity of 
186.6 nmol min-1 g cells-1, which is 3.9-fold larger than the 48.3 nmol min-1 g cells-1 
produced by wild-type.  Additionally, tests indicated that this mutant has two mutations 
at K239R and N275D.  MS-Sc-1 was also tested for isobutene-forming activity in vivo 
and was found to have a 51.6% increase in isobutene production over wild-type.  This 
study validates the mevalonate selection as a strategy to improve MDD activity.  To 
67 
 
 
improve the method further additional methods to decrease revertant phenotypes through 
pathway inhibition are discussed.  
 
Introduction 
The use of petroleum presents myriad problems to our society and the search for a 
renewable source to displace it is desired.  We previously reported on the ability of 
mevalonate diphosphate decarboxylase (MDD) to convert 3-hydroxy-3-methylbutyrate 
(3-HMB) into the valuable platform chemical isobutene (46).  Although MDD is capable 
of catalyzing this reaction with a non-native substrate the activity is too low for practical 
applications and the small but measurable increases that were found from mutant screens 
underlined the need for an efficient selection system to be developed.  An extremely 
useful selection is the growth selection, which is capable of analyzing as many as 1010 
variants per experiment (32).  This type of directed enzyme evolution has been shown to 
be effective in previous work (16), where enzyme efficiency (Kcat/Km) was increased 
10,000-fold using eleven iterations of gene shuffling.  The ability of Castle et al. to 
isolate enhanced mutants from approximately 1.7 × 108 mutants was directly related to 
the efficacy of their selection (16).  A major hurdle to the development of a growth 
selection for our mutants is that isobutene does not have any known physiological 
function with which to build a selection.  However, the decarboxylation of mevalonate, 
which is closer to 3-HMB than the native MDD substrate, could be used to establish an in 
vivo selection.  We hypothesized that a mutation that altered MDD’s structure or function 
to increase its ability to decarboxylate mevalonate to isopentenol may allow it to have 
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more activity to decarboxylate 3-HMB to isobutene.  In this way, the selection would be 
on a substrate that is structurally a step towards 3-HMB from mevalonate diphosphate.  
A key component of our selection process is the gene lytB that codes for the 
enzyme 4-hydroxy-3-methylbut-2-enyl diphosphate reductase.  In E. coli it is used to 
convert 4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMB-PP) into the essential 
isoprenoid biosynthetic precursors isopentenyl diphosphate (IPP) or dimethylallyl-
pyrophosphate (DMAPP) (88).  E. coli uses the non-mevalonate (MEP) pathway to 
produce isoprenoids, and the elimination of lytB has been shown to be a lethal mutation 
(77).  Several groups have reported the use of heterologously expressed mevalonate 
pathway genes for mevalonate-dependent E. coli growth (14, 40, 75, 125).  Unlike the 
mevalonate pathway, where mevalonate is phosphorylated to mevalonate diphosphate 
before being decarboxylated to isopentenyl diphosphate, in our selection mevalonate 
would be decarboxylated and dehydrated into isopentenol.  Essential to our development 
of an isopentenol-dependent E. coli strain was an enzyme capable of phosphorylating 
isopentenol into the key isoprenoid biosynthetic precursor isopentenyl diphosphate (IPP).   
Research has shown that the two known pathways used to make the essential 
isoprenoid biosynthetic precursors IPP and DMAPP are the methylerythritol phosphate 
(MEP) pathway, or the mevalonate (MVA) pathway (76, 79).  The MVA pathway is 
essential to most fungi, plant cytoplasms, and eukaryotes (including humans) for the 
production of polyisoprenoids and sterols, including cholesterol, while the MEP pathway 
is essential for this production in most bacteria, plant chloroplasts, and some eukaryotic 
parasites (79).  Extensive searches of archaea, however, have found the absence of major 
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enzymatic activity attributable to either the MVA or MEP pathway, even though 
isoprenoids are a major component of archaeal lipids (79).  No MDD homologs have 
been found in these archaea through homology searches and this has led some to propose 
a modified MVA pathway in archaea.  In this proposed pathway, a mevalonate 
monophosphate decarboxylase (MPD) is predicted to decarboxylate mevalonate 
monophosphate to isopentenyl phosphate.  During work to identify isoprenoid 
biosynthetic pathway genes in archaea, researchers found an enzyme capable of 
phosphorylating isopentenyl phosphate into isopentenyl diphosphate and characterized 
this ATP dependent reaction of isopentenyl phosphate kinase (IPK) in vitro (6).  IPK 
offered an intriguing way to engineer isopentenol-dependent E. coli growth using two 
genes, IPK and isopentenyl diphosphate isomerase (IDI), to produce the IPP and DMAPP 
from isopentenol needed to circumvent the lytB deletion that knocked out the native MEP 
pathway.  
With an isopentenol-dependent E. coli strain a selection based on the ability of 
mutated mevalonate diphosphate decarboxylase to convert mevalonate to isopentenol was 
hypothesized, which might enable a step-wise approach to improved isobutene 
production by directed enzyme evolution (Fig. 14).  This selection is considered a step-
wise approach because it selects for a reaction whose substrate (mevalonate) is more 
similar to 3-HMB than the native substrate (mevalonate diphosphate).  In this system, 
lytB would be deleted from the E. coli chromosome (Fig. 16).  Since lytB is an essential 
gene, only mutants that produce isopentenol will be able to grow by phosphorylating the 
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isopentenol to isopentenyl diphosphate, which can then be used normally as an 
isoprenoid precursor (Fig. 15).    
   
 
FIG. 14. A step-wise approach to directed enzyme evolution.  On top is the native MDD reaction 
of mevalonate diphosphate conversion to isopentenyl diphosphate, and on the bottom is the target 
3-HMB to isobutene reaction.  Our goal in the mevalonate selection is to engineer a growth 
selection based on an intermediate reaction ‒ mevalonate decarboxylation and dehydration into 
isopentenol. 
 
 
isopentenol
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FIG. 15: The proposed isopentenol pathway.  If mevalonate diphosphate decarboxylase (MDD) 
decarboxylates and dehydrates mevalonate into isopentenol, and if isopentenyl phosphate kinase 
(IPK) is capable of phosphorylating isopentenol into isopentenyl phosphate, a growth selection 
could be built based on the production of the essential isoprenoid biosynthetic precursor 
isopentenyl diphosphate.  Dashed arrows indicate activities that had not been shown prior to our 
tests. 
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FIG. 16. The proposed isopentenol pathway is shown on the far left in the figure, where 
mevalonate is decarboxylated by mutant mevalonate diphosphate decarboxylase (MDD) to 
isopentenol and, using isopentenyl phosphate kinase (IPK), eventually produces isopentenyl 
diphosphate (IPP).  In the middle is the pathway used to reconstitute the mevalonate pathway in 
E. coli, where mevalonate is phosphorylated to mevalonate phosphate to eventually make IPP.  
Key enzymes of this pathway are mevalonate kinase (MVK), mevalonate phosphate kinase 
(MVPK) and mevalonate diphosphate decarboxylase (MDD).  And on the far right is the MEP 
pathway, which is the native pathway in E. coli used to make IPP and DMAPP.  The enzymes 
involved in this pathway are DOXP synthase (dxs), DOXP reductase (IspC), 4-diphosphocytidyl-
2-C-methyl-D-erythritol synthase (IspD), 4-diphosphocytidyl-2-C-methyl-D-erythritol kinase 
(IspE), 2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase (IspF), 4-hydroxy-3-methyl-but-
2-enyl pyrophosphate (HMB-PP) synthase (IspG), and HMB-PP reductase (IspH, LytB).  
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Materials and Methods 
 
Bacterial strains and growth media.  The bacterial strains and plasmids used in 
this study are shown (Table 6).  E. coli was cultured in lysogeny broth (LB) (Difco, 
Detroit, MI) at 37°C (5, 6).  Kanamycin and carbenicillin were used at 50 µg/ml, while 
chloramphenicol and fosmidomycin were used at 20 µg/ml, when necessary.   
Chemicals and reagents.  Antibiotics and DL-mevalonolactone were from Sigma 
Chemical Company (St. Louis, MO).  Isopropyl-β-D-thiogalactopyranoside (IPTG) was 
from Diagnostic Chemicals Limited (Charlotteville PEI, Canada).  Restriction enzymes 
and T4 DNA ligase were from New England Biolabs (Beverly, MA).  3-Methyl-3-buten-
1-ol (isopentenol) and other chemicals were from Fisher Scientific (Pittsburgh, PA).  
Mevalonate was from a 1 M mevalonate stock generated from mixing 1 volume of 2 M 
DL-mevalonolactone with 1.02 volumes of 2 M KOH and incubating at 37°C for 30 min 
as previously described (75).  Arabinose from Sigma Chemical Company (St. Louis, 
MO), was added to 0.1% from a 15% (1 M) stock when needed unless otherwise 
specified.  
Growth assay to verify isopentenol-dependent growth using IPK.  An 
MG1655 E. coli strain with the lytB gene moved and placed under the control of an 
arabinose-inducible promoter, named BE1331, was received from McAteer et al. (77).  
Five strains were developed from BE1331 and isolated as DG87, DG91, DG92, BE1395, 
and BE1396.  These five strains expressed IDI/IPK, IDI, IPK, IDI/MVK/MVPK, or 
IDI/MVK/IPK, respectively.  The five cell lines were also grown in LB medium 
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supplemented with 0.2% glucose to reduce the background growth caused by the 
arabinose promoter, 1 mM IPTG for gene expression, and varying amounts of 
isopentenol.      
Construction of E. coli strains for isopentenol-dependent growth.  
Isopentenol-dependent strains were constructed from NEB 5-alpha E. coli cells obtained 
from New England Biolabs (Beverly, MA).  The lytB gene was knocked out using the 
Wanner method for chromosomal gene knockout (24).  IDI and IPK genes from 
Methanocaldococcus jannaschii were cloned into the pET41a derived plasmid pBE1376 
(Table 6) and transformed into NEB 5-alpha cells.  Once these genes were expressed in 
the cell, the lytB gene could be knocked out.  Next, this strain was transformed with the 
plasmid pKD46, which carries the Red recombinase needed to recombine the linear 
fragment into the chromosome (24).  A previously designed pKD3 plasmid was used as a 
template for the amplification of the chloramphenicol (CAM) fragment (24).  Flanking 
this CAM fragment are FRT (FLP Recognition Target) sites used to FLP the gene out, 
and built into the PCR primer was 40 bp of homology to the chromosomal DNA 
surrounding the lytB gene.  The CAM linear DNA fragment was transformed by 
electroporation and resulted in a chloramphenicol resistant strain of E. coli.  The insertion 
was then verified using PCR, isopentenol growth dependence, and antibiotic sensitivity 
(Fig. 20 & Table 5).     
PCR Verification.  PCR was used to confirm the insertion and FLP recombinase 
process.  Genomic DNA was isolated from 2 ml cultures of lytB knockout mutants using 
the DNeasy Blood and Tissue Kit from Qiagen (Valencia, CA).  The PCR reaction was 
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carried out using KOD Hotstart Mastermix and run for 30 cycles of 95°C for 20 sec, 
50°C for 30 sec, and 70°C for 1 min, followed by 3 min at 70°C.  Three sets of primers 
were used to test the changes in and around lytB.  Primers used were LytB-KO-F 
(TATGATCGACTTCTACGTCGGC) and LytB-KO-R 
(GCGCAATATTGGTTAACGG), LytB F 
(AAGTGCTGGAAATCGATCCGGCACTGGAGGCGTAACATGCAGATCTGTAGG
CTGGAGCTGCTTCG) and LytB R 
(CGGTAACAAGACCGGCATTTTCGCATAACTTAGGCTGCTAATGACATATGAA
TATCCTCCTTAGTTC), or LytB-IPK-F 
(AAGTGCTGGAAATCGATCCGGCACTGGAGGCGTAACATGCAGATCCGACTC
ACTATAGGGGAATTGACA) and LytB-IPK-R 
(CGGTAACAAGACCGGCATTTTCGCATAACTTAGGCTGCTAATGACCCTCCTT
AGTTCCTATTCCGAAGT), and were received from IDT (Coralville, IA).  Control 
PCR reactions using NEB 5-alpha genomic DNA were run for each test (Fig. 21).   
Elimination of antibiotic resistance gene.  The elimination of the 
chloramphenicol resistance gene has been previously described (24).  Briefly, the pCP20 
plasmid has temperature-sensitive replication and thermal induction of FLP synthesis.  
Strains transformed with pCP20 were isolated at 30°C and then streaked onto plates 
placed at 43°C, which results in loss of the plasmid and loss of the chromosomal 
antibiotic resistant gene insert.  Resulting E. coli strains were tested using PCR and 
growth assays to determine those that had lost the pCP20 plasmid and the gene insert. 
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lytB replacement with IPK chromosomal insertion.  pKD3 was used as a 
template to amplify the CAM fragment with FLP flanking sites and subclone this 
fragment into pBE1376-IDI-IPK or pBE1376-IPK.  This added the CAM fragment to a 
plasmid containing the IDI and IPK genes.  Next, this entire fragment (CAM-IDI-IPK or 
CAM-IPK) was PCR amplified with flanking regions of homology for areas surrounding 
lytB, and was inserted into the chromosome.  Strains with successful insertion 
(DG117/DG86-CAM pCP20, which contained IDI-IPK or DG117/DG90-CAM pCP20, 
which contained IPK) were isolated based on their dependence on isopentenol for 
growth, as well as their resistance to chloramphenicol and carbenicillin due to the 
presence of the CAM insert and the pCP20 plasmid (Table 5).  Subsequent FLP removal 
of the CAM fragment produced strains DG129 and DG130, which were dependent on 
isopentenol for growth but became sensitive to chloramphenicol and carbenicillin due to 
the loss of the CAM insert and the pCP20 plasmid (Table 5).  DG129 and DG130 
contained chromosomal insertions of IDI-IPK or IPK at the site of lytB, respectively.  
Growth based analysis showed that the chromosomal lytB knockout with IDI-IPK 
insertion, DG129, and the chromosomal lytB knockout with IPK inserted, DG130, were 
dependent on isopentenol for growth but had become sensitive to chloramphenicol and 
carbenicillin, compared to their resistant parental strains (Table 5). 
Random PCR mutagenesis and sequencing.  The MDD gene was mutagenized 
by error-prone PCR using Clontech’s Diversify PCR Random Mutagenesis Kit and 
primers MDD-F (TAGGTTGAGGCCGTTGAGC) and MDD-R 
(CTCCTTTCAGCAAAAAACCC).  The PCR was run with conditions to incorporate 
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approximately 5 bp changes per 1000 bp of DNA, based on manganese ion 
concentrations.  The PCR was run for 35 cycles of 94°C for 30 sec, 50°C for 30 sec, and 
68°C for 1 min, followed by 1 min at 68°C.  The amplified DNA was then digested with 
BglII and HindIII and then gel purified using a Qiagen QIAquick kit.  Next, the purified 
DNA was ligated into the pET41a derived expression plasmid pBE522.  Ten random 
clones containing the mutated MDD were amplified in DH5α cells.  The pBE522-MDD 
construct was then minipreped and sequenced using PETFOR 
(TAATACGACTCACTATAGGG) and PETREV (GCTAGTTATTGCTCAGCGG) 
stock primers in order to verify mutation frequency.   
Analysis by gas chromatography.  Isobutene was measured using a Varian 
450GC with a CP-Sil 5 CB column fitted with a flame ionization detector.  The method 
used a 10:1 split ratio and a 30-ml/min flow rate with helium as the carrier gas.  The oven 
was held at 30°C for 3 min, which was the duration of the method.  Isopentenol was 
measured by using a Varian 450GC with an HP-5MS column and flame ionization 
detector.  The method used a 10:1 split ratio and a 30-ml/min flow rate with helium as the 
carrier gas.  The oven was held at 40°C for 1 min and then increased to 240°C at a rate of 
10°C per minute. 
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Results 
 
IDI/IPK tests to recover E. coli growth on isopentenol.  An E. coli strain with 
its lytB gene knocked out was acquired.  This strain was constructed by McAteer et al. 
wherein the chromosomal lytB copy was moved to another area of the chromosome and 
placed under the control of an arabinose inducible promoter (77).  With this system, 
growth on LB could be recovered by adding arabinose to the growth medium.  For 
growth of the strain on isopentenol, we expressed the isopentenyl phosphate kinase (IPK) 
and isopentenyl diphosphate isomerase (IDI) genes from Methanocaldococcus jannaschii 
on a pET41a based plasmid.  Previous groups had discovered IPK in archaea and 
characterized it in vitro to find that it phosphorylated isopentenyl phosphate.  If IPK 
could phosphorylate isopentenol and isopentenyl phosphate, it should allow for 
isopentenol-dependent growth of an E. coli lytB mutant.  Results showed that expression 
of IPK and IDI allowed growth on isopentenol by the lytB knockout.  Five strains of the 
E. coli lytB mutant (DG87, DG91, DG92, BE1395, and BE1396) were isolated that 
expressed IDI, IPK, MVK, MVPK, or some combination thereof (See Table 6 for 
details).  In the growth assay all five of the tested strains grew to an OD600 of 
approximately 2.0 when supplemented with arabinose (Fig. 17).   
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FIG. 17. Initial tests on lytB knockout strains to determine growth capabilities of strains 
heterologously expressing combinations of IDI, IPK, mevalonate kinase (MVK), and mevalonate 
phosphate kinase (MVPK).  Results show all five strains capable of inducible lytB dependent 
growth with arabinose supplementation.  Also, IPK alone (strain DG92) can recover isopentenol-
dependent growth but IDI-IPK in combination (strains DG87 and BE1396) enhances the growth 
phenotype. 
 
10 mM isopentenol was capable of recovering growth in all three strains 
expressing IPK (DG87, DG92, and BE1396) (Fig. 17).  From these results, we see that 
IDI alone in DG91 is not capable of growth on isopentenol.  BE1395, which expresses a 
mevalonate phosphate kinase (MVPK), was not capable of replacing IPK for growth on 
isopentenol.  We also see that although E. coli has an endogenous IDI homolog on its 
chromosome, the DG92 strain expressing only IPK does not grow as robustly as DG87 
and BE1396 that express IDI and IPK.  These results indicate that IPK and IDI-IPK are 
capable of full recovery of the growth phenotype in lytB knockout mutants.  
lytB knockout using the Wanner method. The isopentenol growth studies also 
indicated that the lytB gene, under control of an arabinose inducible promoter, is leaky 
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and allows for small amounts of isopentenol-independent growth over time (Fig. 18).  In 
our growth selection, isopentenol-independent growth could create a large amount of 
background colonies that would reduce the efficacy of the selection.     
 
FIG. 18. Isopentenol growth assay after 103 h.  The same cells from fig. 17 were allowed to grow 
for 103 h to see if background growth occurs over time.  We see that over time we have 
additional slow growth from cultures containing 1 mM isopentenol and we also see very small 
growth in strains that lack IPK, such as BE1395.  This slow background growth over time could 
indicate that the arabinose-inducible lytB gene is slightly leaky. 
 
Additionally, the lytB knockout strain (BE1331) is a wild-type E. coli MG1655 strain, 
which has relatively low transformation efficiency.  Hence, the selection strain needed to 
be reengineered.  NEB 5-alpha cells were chosen as host for the reengineered strain due 
to their high transformation efficiency.  With plasmid based IDI-IPK expression and the 
lytB gene deleted the resulting strain required isopentenol for growth to initially produce 
isopentenyl phosphate and then isopentenyl diphosphate (Fig. 16).  This system allows 
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the cell to produce the isoprenoids it needs based on the extraneous supply of 
isopentenol.   
 
 
FIG. 19. Chromosomal map of the lytB area of E. coli.  Arrows indicate the PCR primers (LytB-
KO-F and LytB-KO-R) used to  amplify products of the indicated size in order to diagnose the 
correct insertion of the chloramphenicol gene cassettee (CAM), as well as the FLP product after 
completion of the Wanner method. 
 
In order to verify the construction of the isopentenol-dependent E. coli strain, 
PCR was used to show that the CAM had inserted into the lytB site.  The LytB-KO-F and 
LytB-KO-R diagnostic primers amplify a sequence just flanking the lytB site on the E. 
coli chromosome (Fig. 19).  Insertion of the CAM fragment into the chromosomal lytB 
site was confirmed with a band of 2251 bp and this strain was renamed DG96/CAM (Fig. 
20).   
lytB rihCfkpB
2102 bp
rihC
rihC
fkpB
fkpB
CAM
FLP
2251 bp
1151 bp
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FIG. 20. PCR confirmation, using diagnostic primers LytB-KO-F and LytB-KO-R, of the lytB 
knockout and FLP removal of the CAM gene in the DH5α E. coli chromosome.  The E. coli strain 
with the chloramphenicol gene inserted at the lytB site (DG96/CAM) is the positive control for 
CAM insertion and has a PCR amplicon of 2251 bp.  Three strains with their CAM insert 
removed, 2-1, 20-1, and 20-2, all have the 1151 bp fragment indicating FLP recombination of the 
CAM gene out of the chromosome.   
 
DG96/CAM (shown on the far right of the gel pictured in figure 20) was used as a 
positive control for the insertion of the CAM insert.  Strains isolated from the FLP 
procedure and named 2-1, 20-1, and 20-2 all had an 1151 bp band, which indicated the 
loss of the CAM insert with the FLP sites left as a scar.  The PCR data was further 
confirmed using growth phenotypes to determine the loss of lytB.  The strains became 
and remained dependent on isopentenol for growth, which indicated loss of lytB.  The 
DG96/CAM pCP20 strain could grow on chloramphenicol and carbenicillin, because it 
continued to harbor the insert and plasmid, but the resulting FLP mutants, including 20-1, 
20-2, and 2-1, which was renamed DG102, was sensitive to these two antibiotics due to 
loss of the plasmid and insert (Table 5). 
Kb  2-1  2-2 19-2 20-1 20-2 DG96/
CAM
2251 bp
1151 bp
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Confirmation of lytB replacement using the Wanner method.  The insertion of 
IDI/IPK or IPK into the lytB site of DH5α E. coli was accomplished by diagnostic PCR 
(Fig. 21) and growth phenotype assays (Table 5).  Both DG129 and DG130, which had 
replaced lytB with either IDI/IPK or IPK on their chromosome, respectively, were strictly 
dependent on isopentenol for growth and sensitive to chloramphenicol and carbenicillin.  
The isopentenol dependence indicates loss of the lytB gene with IPK insertion and the 
sensitivity to the antibiotics confirms the FLP removal of the antibiotic resistant cassette 
as well as the plasmid expressing the recombinase.  
 
TABLE 5. Each step in the Wanner method is confirmed both by PCR and growth phenotype 
analysis.  Above is the cell growth analysis that confirms the isopentenol dependence of the lytB 
knockout strains, as well as their antibiotic sensitivity once the CAM fragment has been removed 
using FLP recombinase. An ‘X’ denotes the ability of that strain to grown under the indicated 
condition. 
Strain
DG96/CAM 
pCP20
DG102
Chloramphenicol
X
W/O Isopentenol Carbenicillin
X
With Isopentenol
X
X
DG129 X
DG117/DG86-
CAM pCP20 X X X
DG130
DG117/DG90-
CAM pCP20 X X X
X
  
 
FIG. 21: PCR confirmation of the successful isolation of a DH5
inserted into the chromosome (DG129) or just IPK inserted into the chromosome (DG130).  The 
strains analyzed were DG96, which is a DH5
as the pCP20 plasmid, and its genomic DNA wa
DG117/DG90-CAM #2 are DH5α
IDI/IPK/CAM or IPK/CAM, respectively, inserted into its place.  DG129 
resultant strains of DG117/DG86
CAM fragment had been removed by the FLP recombinase.  Primers used in this PCR were 
LytB-F and LytB-R, which amplifies the CAM fragment flanked by FR
LytB-KO-R, which amplifies outside of the 
and LytB-IPK-R, which amplifies the full insert cassette of either FRT
FRT-CAM-FRT-IPK.   
 
PCR verification of the insertion of IDI and IPK into the 
(Fig. 21).  The LytB-KO-F and LytB
upstream and downstream of the 
from 2,101 bp (indicative of lytB
84 
α lytB mutant with IDI
α strain that contains IDI/IPK on a plasm
s used as a control.  DG117/DG86-
 strains who have had their lytB gene knocked out and either 
and DG130 are the 
-CAM #4 and DG117/DG90-CAM #2, respectively, after their 
T sites, LytB
lytB site on the E. coli chromosome, and LytB
-CAM-FRT-IDI
E. coli chromosome is shown 
-KO-R primers amplify a fragment from sites just 
lytB site.  For this reason, the fragment length increases 
 and flanking DNA), to 2,251 bp when the insert has 
 
-IPK 
id as well 
CAM #4 and 
-KO-F and 
-IPK-F 
-IPK or 
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been made, and finally the size reduces to 1,151 bp when CAM gene is removed.  All of 
which is seen in figure 8 lanes 4, 5, and 6.  Please note that for DG130 creation, these 
lengths in lanes 5 and 6 will be approximately 549 bp shorter due to the absence of IDI.  
Analysis using LytB-IPK-F and LytB-IPK-R, which amplified just the insert fragment, 
was also used to verify the process.  The DG96 has no band correlating to this (lane 7) 
because it does not have this FRT-CAM-FRT-IDI-IPK insert (Fig. 21).  Lane 8 does have 
the band at approximately 2,410 bp representing this fragment (1,861 bp for the DG130 
analysis lane 8).  And after FLP removal of the CAM fragment, lane 9 has the correct 
band size of 1,310 bp or 761 bp for DG129 and DG130, respectively.  This analysis was 
needed to ensure that the correct DNA manipulation occurred with IDI/IPK or IPK. 
lytB replacement using the Wanner method with MaIDI/IPK chromosomal 
insertion. IDI and IPK from Methanocaldococcus jannaschii had successfully allowed 
for isopentenol-dependent growth in an E. coli strain with its lytB gene knocked out.  
However, the minimum amount of isopentenol needed for growth was relatively high and 
the cell’s doubling time was approximately 1.5 times longer than for the E. coli parental 
strain.  So to see if genes from a mesophilic species (Methanocaldococcus jannaschii is a 
hyperthermophile) would work better, a second set of IDI and IPK genes, this time from 
Methanosarcina acetivorans, was used to construct a lytB knockout with the MaIDI/IPK 
genes contained on the pTA925 vector.  This new construct was named DG149 and was 
confirmed through PCR verification and cell growth assays (data not shown).  Analysis is 
ongoing to see if these IDI/IPK variants produce a strain with different growth 
phenotypes.  While tests are ongoing, the isopentenol-dependent strain with 
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Methanocaldococcus jannaschii IDI/IPK integrated into the chromosome was used as the 
primary strain to test ScMDD variants. 
Sequencing of ScMDD mutants generated by PCR random mutagenesis.  
Sequencing of 10 random clones generated by PCR random mutagenesis was done to 
assess the mutation frequency of the library.  The average number of base mutations per 
MDD gene was 4.125 mutations, and the average number of amino acid mutations per 
MDD gene was 3.375 mutations.  This confirmed that the desired mutational frequency 
was obtained and the DNA from this mutant library could be used to select variants with 
enhanced isobutene-forming activity. 
Mevalonate growth selection on plates.  Growth selection using the DG129 
isopentenol-dependent strain was carried out on LB plates containing 10 mM mevalonate 
along with IPTG and appropriate antibiotics.  LB plates with 10 mM isopentenol were 
made for each experiment in order to estimate the transformantion frequency.  From these 
control plates, it was estimated that over 394,000 transformants were plated on 10 mM 
mevalonate plates, with 28 single colonies obtained indicating a frequencing of 1 in 
14,079.  These 28 colonies have turned out to be isopentenol-independent in their growth 
phenotype.  Our hypothesis is that these 28 revertants are capable of growth due to 
remnants of the MEP pathway allowing a recovery of growth upon mutation of an 
endogenous gene, possibly in the MEP pathway itself. 
Isolation of DG129-pBE522-ScMVDCR #9.  The selection using DG129 had 
shown that it was capable of selecting for MDD mutants capable of growing on 
mevalonate.  However, since the only colonies that grew were the 28 isopentenol-
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independent colonies, we hypothesized that the selection is too stringent to overcome 
with the diversity generated by random PCR mutagenesis.  In order to attempt to lower 
the stringency of the selection, small amounts of isopentenol was mixed with mevalonate 
before spreading on LB plates with antibiotics and IPTG.  From these plates 10 colonies 
that grew larger than approximately 120,000 variants, possibly due to improved 
mevalonate decarboxylation, were isolated.  These isolates were then tested for activity to 
decarboxylate and dehydrate mevalonate to isopentenol by gas chromatograph (GC) with 
flame ionization detector (FID).  The amount of isopentenol produced from 1 ml of 
overnight cells in 10 mM mevalonate is shown (Fig. 22).  An isopentenol tester strain 
(DG157) derived from DG129 and containing a pBE522 plasmid expressing the wild-
type ScMDD gene produced 59.3 nmoles of isopentenol in 1 ml of reaction mix.  The ten 
isolated colonies, which contain a pBE522 expressing mutated ScMDD, all produced 
more isopentenol than DG157 except clone number 3 (Fig. 22).  The best producing 
strains were clones number 2, 9, and 13, which produced 191.5, 185, and 218.8 nmoles in 
1 ml of assay mix, respectively, which are 3.2, 3.1, and 3.7 fold increases over the wild-
type strain (Fig. 22).   
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FIG. 22. GC-FID assay to determine the amount of isopentenol produced from 10 mM 
mevalonate by 10 mutants picked on selection plates of mevalonate and small amounts of 
isopentenol.  All mutants besides #3 produced more isopentenol than wild-type ScMDD 
(DG157).  Mutants #2, #9, and #13 had the highest isopentenol production. 
 
Mutant number 9 was chosen for its high isopentenol production, renamed MS-Sc-1, and 
tested for isobutene production from 3-HMB.  MS-Sc-1 had isobutene-forming activity of 
31.2 pmol min-1 g of cells-1, which was a 52% increase over the control.  Additionally, 
MS-Sc-1 was sequenced and revealed to have two amino acid mutations of K239R and 
N275D.  These mutations are not in the active site and so most likely affect enzyme 
activity through indirect conformational changes in the enzyme.  The mutant was also 
retested and found to be dependent on mevalonate or isopentenol for growth.  In order to 
determine the error inherent in the isopentenol GC assay, MS-Sc-1 was assayed for 
isopentenol production against the parent strain (DG157) with six replicates of each (Fig. 
23).  These isopentenol assays showed that MS-Sc-1 had an isopentenol-forming activity 
of 186.6 ± 18.2 nmol min-1 g cells-1.  This is an increase of 3.9-fold over the wild-type 
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(DG157) activity (48.3 nmol min-1 g cells-1 ± 9.8) (Fig. 23).  By adding small amounts of 
isopentenol to the mevalonate selection, 90% of the variants isolated had increased 
activity to decarboxylate mevalonate to produce isopentenol.  Additionally, the one clone 
that was investigated futher (MS-Sc-1) was shown to have an increase in isobutene-
forming activity as well.  These results indicate that adding small amounts of isopentenol 
may be an appropriate strategy in order to reduce the stringency of the mevalonate 
selection and isolate our desired mutants.  The data also indicates that our original 
hypothesis, which was that by selecting for enhanced isopentenol-producing variants we 
would also isolate enhanced isobutene-forming variants, appears to be confirmed. 
 
FIG. 23. Mutant #9 from fig. 22 was renamed MS-Sc-1 and tested multiple times for isopentenol 
producing activity versus the wild-type (DG157).  Six replicates of each were used to develop 
99% confidence intervals and determine the activity of each in nmol min-1 g cells-1.  Results 
showed a 3.9-fold increase in isopentenol-forming activity by the mutant MS-Sc-1. 
 
Examination of revertant phenotype.  The mevalonate selection has yielded 28 
colonies that grew independently of isopentenol or mevalonate.  This indicates that they 
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are either contaminants or revertants.  The frequency of these colonies (1 in 14,079) 
indicates that the genetic changes that are occurring to produce these colonies are single 
mutations.  Although it is very difficult to know the exact cause of the reversion we 
hypothesized that the revertants were using MEP pathway genes or their molecular 
intermediates.  Although lytB had been deleted, the upstream MEP pathway remained 
intact and could build-up intermediates available to MEP pathway genes or other similar 
genes that when mutated could overcome the lytB deletion.   
The antibiotic fosmidomycin was used to test whether MEP pathway 
intermediates were responsible for the reversion.  This antibiotic was originally isolated 
from Streptomyces and inhibits the DXP reductoisomerase in the MEP pathway by acting 
as a structural analog of the native substrate 2-methyl-erythrose 4-phosphate.  
Fosmidomycin’s utility has become more important recently as it has been found to be a 
potent inhibitor of the malaria parasite, which uses the MEP pathway (67, 114).  
Knowing that fosmidomycin should limit the MEP pathway intermediates, it was tested 
on an isopentenol-independent revertant (Fig. 24).  The cells grown simply in LB, labeled 
as ‘LB Cells’ in figure 24, grew to an OD600 of just over 1.6, which confirmed that the 
cells were growing independent of isopentenol and were indeed revertants.  With 
fosmidomycin added to the cells (LB FOS in figure 24), the growth was completely 
inhibited.  In a final condition, the cells were grown in LB with fosmidomycin and 
isopentenol and were able to grow to an OD600 of over 1.8.  This indicates that the 
revertant growth in this isolate is due to MEP pathway intermediates, which is shown in 
their sensitivity to fosmidomycin.  Additionally, isopentenol can recover growth because 
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with the MEP pathway completely shut down, the revertant is again dependent on 
isopentenol for growth, which is not affected by FOS.   
 
FIG. 24. The growth inhibition tests of fosmidomycin (FOS) on a revertant isolated during the 
mevalonate selection.  In this example, cells were capable of overnight growth in LB medium, 
which showed that they were revertants.  With FOS added, the cell growth was almost completely 
inhibited.  And when both FOS and isopentenol were added, cells growth was recovered.  These 
results point to FOS inhibiting MEP pathway intermediates, which prevents the revertants from 
growing, and is only overcome by supplying isopentenol. 
 
Showing that one out of the 28 revertants isolated from the mevalonate growth selection 
is sensitive to fosmidomycin is interesting but it doesn’t indicate a broader trend in these 
revertants.  To see how pervasive MEP pathway intermediates were responsible for 
isopentenol-independent growth, 10 additional revertants were tested for FOS senstitivity 
(Fig. 25).  
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FIG. 25. Of the 28 revertants that were isolated from the mevalonate selection, 10 were randomly 
chosen for tests with fosmidomycin.  All ten were capable of isopentenol-independent growth, 
which is seen in their OD600 readings above 1.6 when grown without FOS.  When FOS is added, 
growth is inhibited in all ten of the clones, which indicates that their revertant phenotype is due to 
elements of the MEP pathway. 
 
All ten of the revertant clones chosen from the 28 revertants that grew on mevalonate 
plates remain isopentenol-independent.  This is shown in figure 8 where all ten have 
OD600 readings above 1.6 when grown in LB without fosmidomycin.  However, when 
FOS is present, none of the revertants are capable of growth (Fig. 25).  This evidence 
corroborates observations made in batch growth (data not shown) that indicates most if 
not all of the revertant phenotypes that have been seen in our selection experiments have 
been sensitive to fosmidomycin inhibition and are most likely due to large quantities of 
MEP pathway intermediates being present in lytB knockout mutants.  Using this 
information we have designed new methods to eliminate these revertants, which will be 
discussed further in the discussion section. 
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Discussion 
In this chapter we described a growth-based selection to improve MDD’s enzyme 
activity and increase the production of the industrially important platform chemical 
isobutene.  We have previously indicated that the activity of MDD on 3-HMB is too low 
for commercial application, and we developed screening methods that yielded several 
mutants with as much as 40-fold increase in in vivo activity (46).  However, this increase 
falls short of our goal of six orders of magnitude increase in enzyme activity, which 
would bring the activity up to approximately the same level as the enzyme’s activity on 
the native substrate, mevalonate diphosphate.  This level of increase would also allow for 
the production of isobutene at a rate of approximately 2 g/L/hr, which we calculate would 
be enough to warrant the capital costs involved in producing isobutene on a commercial 
scale.  This is based on the industry standard for CPI (Cell Performance Index), which is 
measured in grams of product divided by grams of dry cell weight, and is typically 
between 5 and 10 units for economical production.  Based on 2 g/L/hr, we estimate that 
the CPI for isobutene production would be approximately 7.14, assuming 0.28 g dry cell 
weight per liter of LB grown cells, which falls within the 5 to 10 unit zone of economic 
isobutene production.   
In order to achieve that level of production we have demonstrated the design and 
application of a selection method to aid in the isolation of an enhanced isobutene-forming 
variant.  Isobutene itself does not have any known physiological relevance and is also 
volatile, so it is difficult if not impossible to engineer a growth selection based on the 
production of isobutene.  Instead we built an indirect selection based on the 
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decarboxylation of mevalonate, which is closer in structure to 3-HMB than mevalonate 
diphosphate and could allow for a selection based on isopentenol production.  During our 
our work to engineer a mevalonate selection we uncovered an interesting aspect of this 
selection during an anaerobic select (data not shown).  Supplementation with glucose was 
found to severely inhibit cell growth on isopentenol, but the growth inhibition could be 
overcome during growth on mevalonate with a mevalonate kinase (MVK) gene present.  
The results indicate that inhibition by glucose occurs during the initial phosphorylation of 
isopentenol to isopentenyl phosphate, and most likely points to IPK only being 
responsible for the second phosphorylation of isopentenyl phosphate to isopentenyl 
diphosphate (IPP).  We hypothesize that glucose suppresses the expression of an 
endogenous kinase that phosphorylates isopentenol, but additional testing would be 
needed to confirm this observation.    
At this point, we have isolated 28 variants that grow on mevalonate plates.  
However, we have found that these mutants are not dependent on mevalonate for growth, 
which indicates that the mutants have found a way to bypass the lethal growth phenotype 
of the lytB deletion.  Many factors could be used to overcome a lytB deletion, such as a 
change-of-substrate mutation or the alteration of a key regulatory element.  Our initial 
studies using the antibiotic fosmidomycin (FOS) have shown that all of the revertants are 
inhibited by FOS.  This appears to indicate that the presence of MEP pathway 
intermediates is most likely the reason that some cells are able to grow independent of 
isopentenol.  With this knowledge in hand we have identified upstream MEP pathway 
genes, including the ispD gene, as a gene target to knockout.  If the MEP pathway 
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intermediates are causing the revertants, knocking out this gene might significantly 
reduce revertant frequency and allow for a selection system that would analyze a greater 
number of variants, such as in an enrichment culture.   
The reason we have only seen revertants in our mevalonate growth selection 
experiments is most likely due to the high stringency of the test – the needed mutation or 
combination of mutations is too rare a mutation that would lead to a variant capable of 
growth exclusively on mevalonate.  Our tests to lower the stringency of the mevalonate 
growth selection by adding small amounts of isopentenol resulted in the isolation of 
variants with higher mevalonate decarboxylase activity as well as higher isobutene-
forming ability.  These isolates indicate that our approach of using an isopentenol-
dependent strain for the isolation of variants with higher mevalonate decarboxylase and 
3-HMB decarboxylase activity is promising.   
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TABLE 6. Bacterial strains and plasmids used in this study. 
 
Strains Description Source 
DH5α fhuA2 ∆(argF-lacZ)U169 phoA glnV44 φ80∆ (lacZ)M15 
gyrA96 recA1 relA1 endA1 thi-1 hsdR17 
New England 
Biolabs 
DH10β araD139 ∆(ara,leu)7697 fhuA lacX74 galK (φ80 ∆(lacZ)M15) 
mcrA galU recA1 endA1 nupG rpsL (StrR)∆(mrr-hsdRMS-
mcrBC) 
New England 
Biolabs 
BE1331 E. coli MG1655 ∆lytB  LytB moved and placed under 
arabinose promoter 
(77) 
BE1395 BE1331 with pLac22-IDI-MVK-MVPK This study 
BE1396 BE1331 with pLac22-IDI-MVK-IPK This study 
DG86 DH5α with pBE1376-IDI-IPK This study 
DG87 BE1331 with pBE1376-IDI-IPK This study 
DG90 DH5α with pBE1376-IPK This study 
DG91 BE1331 with pBE1376-IDI This study 
DG92 BE1331 with pBE1376-IPK This study 
DG96 DH5α with pTA925/IDI-IPK and pKD46 present This study 
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Table 6. (continued) 
DG100 DH5α with pTA925/IDI-IPK and lytB knocked out with CAM 
inserted in its place.  Also contains pCP20 plasmid 
This study 
DG102 DH5α with pTA925/IDI-IPK and lytB knocked out with CAM 
FLP’d out 
This study 
DG127 DH5α with lytB knocked out with CAM inserted in its place. 
IDI and IPK inserted at lytB site 
This study 
DG129 DH5α with lytB knocked out with CAM FLP’d out. IDI and 
IPK inserted at lytB site 
This study 
DG128 DH5α with lytB knocked out with CAM inserted in its place. 
IPK inserted at lytB site 
This study 
DG130 DH5α with lytB knocked out with CAM FLP’d out. IPK 
inserted at lytB site 
This study 
DG149 DH5α with lytB knocked out with CAM FLP’d out. MaIDI-
IPK inserted at lytB site 
This study 
DG157 DH5α with lytB knocked out with CAM FLP’d out. IDI and 
IPK inserted at lytB site and pBE522-ScMDD 
This study 
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Table 6. (continued) 
Plasmids   
pDG86 pBE1376/IDI-IPK This Study 
pET41a KmR; T7 expression vector Novagen 
pTA925  KmR, pET41a derivative with a 5’ BglII cloning site (55) 
pBE522 KmR, pET41a derivative with an E. coli consensus promoter T.A. Bobik 
Collection 
pKD3 AmpR , Contains the chloramphenicol cassette with FRT sites (24) 
pKD46 AmpR , Encodes the Red recombinase (24) 
pCP20 AmpR , FLP helper plasmid (24) 
pBE1376 AmpR, pBE522 derivative T.A. Bobik 
Collection 
pLac22 AmpR, Expression plasmid (123) 
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Chapter 5. Development of an Isobutene Biosensor 
 
 
Abstract 
The purpose of this study was to determine whether a transcriptional regulator 
could be discovered, that interacts with isobutene, in order to build an in vivo isobutene 
biosensor for a growth-based selection.  A toluene biosensor based on the known 
transcriptional activator (TbuT) was investigated for its ability to respond to isobutene.  
The biosensor was monitored for isobutene induction both in Pseudomonas fluorescens 
as well as in E. coli and was determined to respond to isobutene with isobutene 
concentrations of at least 1,000 to 10,000PPM when induced in P. fluorescens.  
Additional improvements were made to the biosensor in order for induction to occur in E. 
coli, including changing the plasmid system and optimizing the TbuT for codon usage in 
E. coli.  With these modifications, induction of LacZ expression was seen in E. coli for 
toluene, isobutene, and isoprene, at induction ratios of 1.64, 3.58, and 1.3, respectively.  
We discuss the potential to use TbuT as an in vivo biosensor to respond to isobutene and 
express an antibiotic resistance gene in order to select for mevalonate diphosphate 
decarboxylase (MDD) mutants with higher isobutene-forming ability. 
 
Introduction 
A major goal of my thesis research is producing renewable isobutene from 
glucose.  Our approach is to use MDD however its activity is too low.  Previous work has 
shown improvement of enzyme activity up to 10,000-fold by coupling gene shuffling and 
a robust selection (16).  Our desire to increase MDD by as much or more necessitates 
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large mutagenic libraries, which requires an efficient screening method based on a way to 
correctly identify the desired positive outcomes.  In order to analyze such a large library, 
a selection capable of analyzing 1010 mutants at a time is required (32).  We have 
previously developed an in vivo selection based on the decarboxylation of mevalonate to 
form isopentenol.  This was done because of the difficulty in developing a sound 
selection method based on the production of isobutene.  Isobutene is a volatile 
hydrocarbon and there are no known pathways to link it metabolically to cell survival and 
growth.  A biosensor capable of detecting increased isobutene production could allow us 
to build a growth selection. 
Extensive work has been done on developing bacterial biosensors for a wide 
range of applications (2, 15, 68, 86, 106, 126).  Some biotech companies have discovered 
and developed biosensors that respond to hydrocarbons produced in vivo, and used these 
systems to isolate important hydrocarbon producing genes (98).  However, these sensors 
have all been based on the detection of medium to large chain hydrocarbon molecules, 
and no record of a biosensor for small alkanes or alkenes has been identified, to our 
knowledge.  One important biosensor from the biotech company LS9 was based on the 
alkane response element (ARE) discovered in Acinetobacter by Ratajczak’s group in 
1998 (89).  This ARE is based on the Acinetobacter strain’s inherent ability to degrade 
alkanes.  The alkR transcriptional activator responded and expressed alkM upon induction 
by middle and long-chain alkanes (above heptanes) (89).  Additional middle and long-
chain alkane biosensors have been discovered, including the alkB/alkS system (89).  A 
transcriptional regulator that could interact with isobutene and relay that signal to a 
plasmid based promoter could be linked to the expression of an antibiotic resistance gene 
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or other gene that permitted cell survival and growth for the desired enzyme mutant.  
However, up to this point no transcriptional regulator had been shown to respond to 
isobutene. 
Halverson et al. used a plasmid based biosensor system that reports the 
transcription from a toluene-responsive promoter (15).  Previous work had found a 
transcriptional activator from Ralstonia pickettii named TbuT that expresses a toluene 3-
monooxygenase in the native host when induced by toluene.  Halverson constructed a 
biosensor that used TbuT to activate a promoter fused to a promoter-less GFP reporter 
gene (15).  The goal of the project was to build a biosensor capable of identifying soil and 
water contaminated with toluene, benzene, and xylene (107).  Fluorescence data was 
generated for a range of alcohols, alkenes, and alkanes that presented a picture of the 
types of molecules that could activate TbuT (107).  Although small molecules such as 
ethanol and butanol did not activate TbuT, the ability of 2-methyl-2-butene to activate 
TbuT was an important factor in our decision to look further into the possibility of using 
TbuT for isobutene detection.  This TbuT biosensor was constructed by Halverson et al. 
in the pTS plasmid, which is based on a pGEM-7 (Promega) construct (107).  This 
plasmid uses the pVS61/p15a origin of replication capable of replication in both E. coli 
and in Pseudomonas fluorescens.  The pTS based TbuT biosensor used green 
fluorescence protein (GFP) from Aequoria victoria as the reporter gene, placed under the 
control of the TbuT promoter PtbuA1 (107).  
An adaptation of this system was used by Tecon et al. in order to construct an E. 
coli based biosensor capable of detection of oil spills in sea water via a luminescence 
reporter gene (110).  Halverson’s pTS biosensor had failed to respond even to toluene in 
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E. coli.  So Tecon et al. decided to move the TbuT construct into a pPROBE vector with 
a pBBR1 backbone and replaced the GFP with the luminescence reporter gene LuxAB 
(110).  LuxAB luminescence is an extremely sensitive method to detect protein 
expression and requires an exogenous substrate, such as decanal, to be added for 
luminescence to occur.  With their success in an E. coli host, and given that the 
transcriptional activator responds to a variety of molecular targets that are similar to 
isobutene, we planned to test and construct a selection system based on the ability of 
TbuT to respond to isobutene.   
 
Materials and Methods 
 
Bacterial strains and growth media.  The bacterial strains and plasmids used in 
the study are shown in Table 8.  E. coli was cultured in lysogeny broth (LB) (Difco, 
Detroit, MI) at 30°C or 37°C (5, 6).  Kanamycin was used at a concentration of 50 µg/ml, 
when necessary.  M9 medium was used for defined medium induction studies (MP 
Biomedicals, Solon, OH).  MOPs defined medium was used for some luminescence 
studies described previously (110).  
Chemicals and reagents.  Antibiotics were from Sigma Chemical Company (St. 
Louis, MO).  Isopropyl-β-D-thiogalactopyranoside (IPTG) was from Diagnostic 
Chemicals Limited (Charlotteville PEI, Canada).  Restriction enzymes and T4 DNA 
ligase were from New England Biolabs (Beverly, MA).  Ethidium bromide, 2-
mercaptoethanol, and SDS were from Bio-Rad (Hercules, CA).  Other chemicals were 
from Fisher Scientific (Pittsburgh, PA). 
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Fluorescence induction studies.  Pseudomonas pTS biosensor (DG79) or E. coli 
pTS biosensor (DG80) were grown overnight in LB with appropriate antibiotics.  200 µl 
of overnight culture was used to inoculate 1.8 ml fresh LB and the mixture was placed in 
a 10 ml screw cap vial with a PTFE gas-tight cap.  Isobutene was added to the amounts 
indicated and the cells were incubated for 3 h at 30°C for DG79 or 37°C for DG80.  
Following induction, cell density was measured at OD600 and then the fluorescence was 
read using a Biotek microplate reader with a 96-well fluotrac 600 microplate.  GFP was 
excited at 485 nm and measured at 528 nm.  The fluorescence data was expressed in the 
instrument’s arbitrary relative units and the relative fluorescence units (RFU) were 
calculated by dividing the fluorescence units by the OD600 reading of the cells.   
Luminescence data on microplate reader.  Luminescence was measured in an 
E. coli pPROBE-LuxAB-TbuT biosensor (DG82) grown overnight in LB with 
appropriate antibiotics.  500 µl was used to inoculate 1.5 ml of LB medium in a 10 ml 
screw cap vial with a PTFE gas-tight cap.  Isobutene was then added to the headspace 
and the cells were incubated overnight at 30°C.  Following induction, cell density was 
measured at OD600 and the cells were diluted in order to equalize their cell densities.  
Then 200 µl of each sample was added to a 96-well plate and 20 µl of an 18 mM n-
decanal solution was added.  After 3 min of incubation at room temperature the 
luminescence was measured using a Biotek microplate reader at 490 nm. 
Luminescence data on luminometer.  DG82 was grown overnight in LB with 
appropriate antibiotics.  The cells were then pelleted and resuspended in an equal volume 
of MOPs medium.  500 µl of these cells were then used to inoculate 1.5 ml MOPs 
medium and the 2 ml was placed in a 10 ml screw-cap vial with PTFE gas-tight cap.  
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Isobutene was then added to the headspace and the cells were incubated overnight at 
37°C.  Following induction, cell density was measured at OD600 and the cells were 
diluted in order to equalize their cell densities. 50 µl of induced cells were added to 150 
µl of MOPs medium and placed into a 96-well white opaque plate and 20 µl of an 18 mM 
n-decanal solution was added.  Luminescence was read at several time points using a 
luminometer at 490 nm.  
Construction of the E. coli LacZ biosensor.  The pTS biosensor construct was 
received from Larry Halverson for initial tests.  pPROBE-LuxAB-TbuT construct was 
received from Jan Roelof van der Meer.  After tests using these constructs, it was 
determined that improvements could be made to enhance the biosensor’s performance in 
E. coli.  To do this, the biosensor fragment was synthesized by Genscript with TbuT 
codon optimized for E. coli host expression.  The neomycin promoter (nptII) was 
replaced by an E. coli constitutive promoter.  Also, the sequence was altered in order to 
create unique restriction sites so that TbuT, the E. coli promoter, the PtbuA1 promoter, 
and the reporter gene could all be moved and subcloned as necessary.  This biosensor 
(BS) fragment construct contained the E. coli constitutive promoter transcribing TbuT 
inverted from the TbuT promoter and reporter gene.  The BS fragment was received from 
Genscript in the pUC57 maintenance plasmid and subcloned into the pET41a expression 
vector.     
β-Galactosidase assay.  Cells were streaked or plated onto M9 or LB plates and 
grown at 30°C for two days.  When induction by isobutene was monitored, plates with 
cells were grown in a GasPak anaerobic system from Becton, Dickinson and Company 
(Sparks, MD) with isobutene as the headspace.  Once cells had grown, they were 
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suspended in 0.85% saline solution and their OD650 was checked.  Cells were then 
diluted to equilibrate cell densities, and then 500 µl of cells were added to a glass tube 
containing 500 µl Z-buffer with β-mercaptoethanol, 100 µl chloroform and 50 µl 0.1% 
SDS in order to disrupt the cell membrane.  Cells were vortexed 3 seconds and 200 µl of 
ortho-nitrophenyl-β-galactoside (ONPG) stock (4 mg/ml) was added to initiate the 
reaction.  The assay was then incubated at 37°C until a faint yellow color appeared.  
Reaction was stopped by adding 500 µl of 1M Na2CO3 and the assay was incubated an 
additional 5 minutes.  The assay was then centrifuged at 16000g for 5 min and the 
absorbance was read using a spectrophotometer at OD420 and OD550.     
Counter-selection.  A counter-selection system was engineered to improve the 
biosensor induction, based on previous work (80).  In this system, a tetracycline 
resistance gene TetA is used to select for the on and off expression of the biosensor 
system.  For this setup, the TetA gene was placed as the downstream reporter gene in the 
biosensor construct, under the control of the PtbuA1 promoter.  Mutational diversity was 
engineered into the biosensor construct via mutagenic PCR or XL1-Red mutagenesis.  
TbuT was induced using 3 mM toluene in 10 ml screw-cap GC vials containing 2 ml of 
M9 medium with cells and appropriate antibiotics and supplements for growth.  Cells 
were grown 8 hours at 37°C for induction to occur, before the cells were diluted in M9 
medium and tetracycline added to the indicated levels.  These cells grew for 24 hours 
before the most Tet resistant variants were isolated and grown in a non-induced fashion 
for 8 hours.  Next, the cells were diluted into M9 and NiCl2 was added to the indicated 
amounts.  These cells grew for 24 hours before the best growing variants were isolated, 
and the process was repeated. 
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Results 
 
Fluorescence data.  Initial tests to determine isobutene inducibility of the pTS 
biosensor were carried out using green fluorescence protein (GFP) as the reporter gene.  
Figure 26 shows the 3 hr induction of DG79 and DG80 using 0PPM or 100,000PPM 
isobutene (Fig. 26).  Tests show a significant increase in fluorescence of the 
Pseudomonas (DG79) upon induction but little or no induction from the E. coli based 
(DG80) system.  Relative fluorescence units (RFU) increased for DG79 from 85.7, when 
the cells were uninduced, to 673.8 RFU when isobutene was present in the headspace at 
100,000PPM.  This constitutes an induction ratio of 7.86.  DG80 had RFU readings go 
from 429.3 to 430.1 indicating that no induction occurred under these conditions with this 
system. 
To measure the sensitivity of the pTS system in DG79, the induction was 
measured after 24 h incubation at 30°C with varying amounts of isobutene (Fig. 27).  
Clear induction is seen once the isobutene concentration reaches 10,000PPM.  RFU 
readings stay at around 250 for isobutene headspace amounts of 0, 100, and 1,000PPM, 
but increase to 1124 RFU for 10,000PPM isobutene, and 4041.7 RFU for 100,000PPM 
isobutene.  This indicates an induction ratio for the DG79 construct of 4.5 and 16.1 for 
10,000PPM and 100,000PPM isobutene over the baseline, respectively.  These induction 
ratios are within the same range as those values found in Pseudomonas with induction by 
toluene (14.2 induction ratio) and 2-methyl-2-butene (6.5 induction ratio) (107). 
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FIG. 26.  Fluorescence response to isobutene using the pTS vector in Pseudomonas (DG79) or E. 
coli (DG80).  Induction is clearly seen in DG79 when 100,000PPM isobutene is added to the 
headspace.  No induction is seen in the E. coli based system.     
 
 
 
FIG. 27. Fluorescence assay to determine the sensitivity of the Pseudomonas based biosensor to 
isobutene.  Induction was seen after the addition of at least 10,000PPM isobutene and induction 
ratios of 4.5 and 16.1 were seen with the introduction of 10,000PPM and 100,000PPM into the 
headspace.  
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Luminescence data.  Since the pTS based fluorescence biosensor failed to 
measure any induction by toluene or isobutene in E. coli, we needed an alternative.  A 
report from Tecon et al. had indicated that a luminescence based biosensor in an 
alternative plasmid (pPROBE) could respond to toluene in E. coli.  Isobutene induction 
of this construct was measured (Fig. 28).  Two samples of the E. coli based pPROBE-
TbuT-LuxAB (DG82) cells were induced side by side in 0, 1,000, 10,000 or 100,000PPM 
isobutene.  These cells were then assayed for luminescence 20 minutes after decanal 
addition.  This was the initial test of the pPROBE-LuxAB-TbuT system in E. coli.  This 
system was intended to enhance the TbuT transcriptional activator’s ability to respond in 
E. coli where the DG80 system failed.  Average luminescence readings for the two 
samples increased from the 0PPM isobutene background of 25 units to 90, 285, and 500 
units for 1,000, 10,000, and 100,000PPM isobutene, respectively.  This constitutes a 
luminescence induction ratio of 3.6, 11.4, and 20 for the three isobutene concentrations 
and also indicates that the minimum level of isobutene needed for luminescence 
induction readings is around 1,000PPM isobutene.  
An additional test was done with DG82 using a luminometer for additional 
confirmation of LuxAB induction by isobutene.  The cells were incubated in sealed vials 
with 0, 10,000, 50,000, or 100,000PPM isobutene in the headspace and monitored 20 
minutes after decanal addition in triplicate.  99% confidence intervals are shown (Fig. 
29).  Luminescence units increase from 17,941 for the uninduced cultures to 18,806, 
26,318, and 38,922 units for 10,000, 50,000, and 100,000PPM isobutene, respectively.  
Induction ratios appear smaller in the luminometer, possibly because of a large increase 
in background readings for the uninduced cultures.  Based on the confidence intervals, 
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the luminescence data indicates approximately 50,000PPM of isobutene is needed for 
induction and detection of the biosensor in E. coli.   
 
FIG. 28. Luminescence assay to determine the E. coli based biosensor’s sensitivity to isobutene.  
DG82 responded to isobutene concentrations as low as 1,000PPM.  Induction ratios of 3.6, 11.4, 
and 20 were seen for isobutene levels of 1,000, 10,000, and 100,000PPM.  
 
 
 
FIG. 29. Luminescence assay to determine minimum amount of isobutene needed for a response 
from E. coli using the biosensor with the LuxAB reporter gene (DG82).  Luminescence was 
detected 20 minutes after decanal addition using a luminometer.  
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β-Galactosidase assay.  The LuxAB gene in the pPROBE based biosensor was 
then replaced by LacZ as the reporter gene to create DG94.  This construct was placed in 
E. coli and assayed for LacZ expression using the β-galactosidase assay (Fig. 30).  The 
assay was run for 7 minutes at 37°C before stopping with Na2CO3.  The LacZ activity 
was measured by spectrophotometer and calculated as miller units, (µmol/min/OD650).  
The miller units were 411.7, for the DG94 grown without isobutene, and 886.4 for the 
culture induced with isobutene.  This is an induction ratio of 2.15-fold for isobutene 
induction of the pPROBE-TbuT-LacZ system. 
With this data, we could see that LacZ could be used as an efficient reporter gene, 
but the induction ratio would need to be improved for utilization of the biosensor in a 
selection strain.  In order to improve the biosensor, it was reconstructed and placed in a 
medium-copy plasmid (pET41a) and the TbuT gene was codon optimized.  Additionally, 
the neomycin constitutive promoter expressing TbuT was replaced with an E. coli 
constitutive promoter.  This new construct, named DG112a, was transformed into E. coli 
and the β-galactosidase assay was used to determine the expression of LacZ when 
induced by isobutene (Fig. 31).  The assay was run in triplicate and run for 3 minutes at 
37°C before stopping with Na2CO3.  Average miller units were calculated as 2222 for the 
uninduced cells and 3652 for cells induced with isobutene.  This is an induction ratio of 
1.64 (Table 7). 
Additional β-galactosidase assays were conducted in order to measure the ability 
for the known inducer toluene to activate LacZ expression.  Along with toluene, the 
industrially and commercially important molecule isoprene was also tested for induction 
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of β-galactosidase activity (Fig. 32).  As much as 800,000 tonnes of isoprene are made 
annually from oil, and almost all of this production is used to make cis-1,4-polyisoprene, 
which is a synthetic version of natural rubber used to make automobile tires (132).  
Companies, such as Genencor, have developed isoprene production in microorganisms, 
and a biosensor used to increase this biological activity would be of great interest.  In the 
β-galactosidase assay, toluene strongly induces the TbuT biosensor (Fig. 32).  Although 
the induction of the system by isoprene was relatively small, the induction is statistically 
significant and underscores the versatility and potential importance of this biosensor.  
The concentration of toluene and isoprene needed for biosensor response was also 
monitored with the β-galactosidase assay.    
 
FIG. 30. β-galactosidase assay using an E. coli based pPROBE vector containing the biosensor 
cassette (DG94).  Isobutene headspace concentrations of 10000PPM yielded an induction ratio of 
2.15.  
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FIG. 31. β-galactosidase assay to determine amount of isobutene induction on E. coli based 
pPROBE vector containing the  modified biosensor cassette (DG112a).  An induction ratio of 
1.64 was seen with this biosensor construct.  
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FIG. 32. β-galactosidase assay to determine the substrate specificity of E. coli based biosensors 
DG94 and DG112.  Isobutene, isoprene, and toluene all showed statistically significant induction 
of the biosensor.  
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE 7. Induction ratios for the E. coli based biosensors DG94 and DG112.   Statistically 
significant induction of the biosensor was seen for isobutene, toluene, and isoprene.  
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DG112a Substrate Specificity
Induction 
Method 
Induction 
Ratio 
DG94 Isobutene 2.15 
DG112 Isobutene 1.64 
DG112 Toluene 3.58 
DG112 Isoprene 1.3 
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Toluene and isoprene were added to 100 µM or 5 mM concentrations for each compound 
and the biosensor response was monitored in triplicate (Fig. 32).  Uninduced cells had 
2,203 miller units of activity, compared to 3,706 and 7,893, for the two toluene 
concentrations, and 2,524 and 2,860 for the two isoprene concentrations (Fig. 32).  99% 
confidence intervals are shown for each condition monitored and the lowest isoprene 
concentration is just beyond the 99% confidence interval to be statistically higher than 
uninduced cells.  The higher concentration of isoprene, as well as both toluene 
concentrations, is clearly higher than uninduced cells (Fig. 32).  Induction ratios of the 
DG112a biosensor when induced by isobutene, toluene, and isoprene, were 1.64, 3.58, 
and 1.3, respectively (Table 7).  
Counter-selection.  The counter-selection was used to improve the biosensor’s 
sensitivity and induction ratio.  So far, none of the isolates from this selection have been 
improved variants.  This is most likely due to the initial ON selection where a minimum 
of 10 µM tetracycline is used.  This amount appears to select for mutations that lock the 
biosensor in a constitutive ON position so that the uninduced cultures have very high 
background expression, even after selection with NiCl2.  Future experiments will attempt 
to fine-tune these tetracycline concentrations in order to gradually increase the 
biosensor’s induction ratio. 
 
Discussion 
The development of an efficient selection for isobutene production is critical to 
our goal of improving MDD activity by several orders of magnitude though directed 
enzyme evolution.  Moreover, the development of an isobutene biosensor could allow for 
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the metagenomic investigation of other potential isobutene-forming genes.  Also, small 
molecules that are similar to isobutene in structure, such as isoprene, are also considered 
as valuable intermediates and their production could be improved significantly if a 
biosensor-based selection system existed.  Isoprene is produced naturally in small 
quantities in plants and other organisms, but it is made industrially on a large scale from 
petroleum.  Isoprene is used for synthetic rubber synthesis and has even been proposed as 
an important jet fuel component (132).  Recently, groups have engineered isoprene 
production into E. coli by improving its production from the methylerythritol phosphate 
(MEP) pathway (132).  This pathway has been engineered with the isoprene synthase 
(ispS) gene from Populus nigra for the conversion of dimethylallyl diphosphate 
(DMAPP) to isoprene (132).  If a system could be built to detect the presence of 
isobutene in vivo and link that detection to a method of selecting for those cells with 
heightened production. 
Our data points to the fact that TbuT can respond to molecules such as isobutene 
and isoprene in an E. coli host.  Unfortunately, it is also apparent that the system in E. 
coli does not have an induction ratio as large as if the biosensor were in a different host, 
Pseudomonas fluorescens.  The reason for this disparity is most likely due to the use of a 
sigma-54 factor to respond to TbuT stimulus for protein expression.  E. coli have a 
greater number of sigma-54 factors available, which ultimately could lead to a larger 
background for uninduced cultures (57). 
An additional factor to consider in our analysis is our use of a medium copy 
number plasmid (pET41a) as a host vector for expression of the biosensor cassette.  The 
potential problem with using a multicopy plasmid versus the low copy pPROBE vectors 
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is that background noise from uninduced cultures can be amplified to a greater extent.  
All of the factors could come together to dilute the induction ratio.   
Ultimately, our work affirms the ability to construct a biosensor capable of 
identifying isobutene.  Additional work is required, however, before the full biosensor 
can be implemented as intended – which is as a biosensor fused to a reporter gene, such 
as the TetA gene coding for tetracycline resistance, in order for the biosensor to confer 
antibiotic resistance on mutants with higher isobutene-forming capabilities.  This process 
necessitates a clear distinction in protein expression at isobutene levels that are relevant 
to the mutants we are currently producing in the lab.  In other words, we have two 
hurdles to overcome to allow for further development of the isobutene biosensor.  The 
first is that the sensitivity of the biosensor must be increased so that a lower amount of 
isobutene is required for a large response.  And the second hurdle is that the induction 
ratio must be larger in order to have a clear distinction between those mutants producing 
more isobutene and those that are not. 
Several methods to address the two issues listed above have been considered and 
implemented to improve the isobutene biosensor.  Initial estimates would point to the 
need for isobutene responses to occur at or around 1,000 to 10,000PPM isobutene 
headspace concentrations, which is approximately 10 to 100 times more sensitive than 
current iterations of the sensor.  This amount of isobutene in the headspace would 
approximately coincide with the amounts currently being produced.  An additional factor 
that we have considered is the apparent intracellular isobutene concentrations that might 
occur with an active MDD-biosensor dual plasmid system.  If MDD is producing 
isobutene inside a cell with the biosensor, the apparent isobutene concentration might be 
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higher than the extracellular concentration and allow the biosensor to work even with 
lower sensitivity.  We also estimate that a significantly higher induction ratio is needed 
for a sufficient selection to occur using tetracycline resistance.  In order to improve the 
biosensor by these amounts, an efficient selection system is required. 
Although the irony of improving a desired selection system using a selection 
method on the biosensor itself is not lost on us, there has been significant research in this 
area (80, 84, 109).  Future work to improve the isobutene biosensor will include the use 
of two methods.  The first is to use the XL1-Red mutagenesis system to introduce random 
mutations throughout the pET41a-BS construct, and screen for desired mutants.  The 
second method is to use a counter-selection system, such as the one described by 
Yokobayashi et al. (80).  This method uses the expression of TetA as the reporter gene to 
select for tetracycline resistant mutants when induced, but also selects for reduced 
background in uninduced mutants because of the cell’s NiCl2 sensitivity when expressing 
TetA.  This sensitivity occurs due to the expression of the TetA protein, which is 
membrane bound and increases the cell’s sensitivity to toxic metal salts such as NiCl2 
(80).  This method, after several rounds of selection, should enhance the biosensor’s 
induction ratio. 
Finally, the choice of the TbuT transcriptional activator for tests to see if it 
responded to isobutene was based on the best information documented on the substrate 
specificity of TbuT.  However, there are other similar transcriptional regulators that 
should be tested in addition to TbuT in order to see if their specificity and function in E. 
coli is more closely tied to isobutene.  These include the toluene-2-monooxygenase 
regulator from Pseudomonas TbmR (64), the middle-chain transcriptional regulator alkR 
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from Acinetobacter (89, 107), and the transcriptional regulator of the alkene 
monooxygenase pathway identified in Xanthobacter Strain Py2 (10, 38, 134), are all 
candidates for use as transcriptional regulators in an isobutene biosensor. 
  
TABLE 8. Bacterial strains and plasmids used in this study. 
 
Strains Description Source 
DH5α fhuA2 ∆(argF-lacZ)U169 phoA glnV44 φ80∆ (lacZ)M15 
gyrA96 recA1 relA1 endA1 thi-1 hsdR17 
New England 
Biolabs 
DH10β araD139 ∆(ara,leu)7697 fhuA lacX74 galK (φ80 ∆(lacZ)M15) 
mcrA galU recA1 endA1 nupG rpsL (StrR)∆(mrr-hsdRMS-
mcrBC) 
New England 
Biolabs 
DG79 Pseudomonas fluorescens A506-pTS (107) 
DG94 DH5α/pPROBE-TbuT-LacZ This study 
DG112a DH5α/pET41a-BS-LacZ This Study 
DG80 DH5α/pTS (107) 
DG82 DH5α/pPROBE-LuxAB-TbuT (110) 
DG97 DH5α/pPROBE-TbuT-TetA This Study 
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Table 8. (continued) 
Plasmids   
pET41a KmR; T7 expression vector Novagen 
pTA925  KmR, pET41a derivative with a 5’ BglII cloning site (55) 
pTS KmR, pPROBE  (p15a origin) carrying the PtbuA1-PnptII-
tbuT cassette 
(107) 
pPROBE KmR; Broad-host-range promoter-probe vector (78, 82) 
pET41-BS KmR, pET41a plasmid carrying a modified PtbuA1-Pecoli-
TbuT cassette 
This work 
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Chapter 6.  Synthetic Gene Shuffling to Expand  
Mevalonate Diphosphate Decarboxylase Sequence Diversity 
 
Abstract 
Synthetic gene shuffling based on six MDD homologs was used to build libraries 
of chimeric mevalonate diphosphate decarboxylases that were selected for improved 
mevalonate decarboxylation using an isopentenol-dependent E. coli strain.  30 
oligonucleotides were built to synthesize a full length decarboxylase and incorporate 
genetic variation by PCR.  62 amino acid sites were varied and constituted a maximum 
theoretical library size of 2.3 × 1019 possible combinations, which is consistent with 
previous work (82).  Our studies show that MDD was completely reconstituted in 15 
random colonies sequenced with 2 in 15 bearing a mutated MDD sequence with no 
frame-shift mutations.  From this library we have selected for 186,800 colonies and so far 
zero mevalonate dependent colonies have been isolated.   
 
Introduction 
The search for a biological pathway to produce fuels and chemicals capable of 
displacing petroleum is ongoing (62, 95).  Our discovery that mevalonate diphosphate 
decarboxylase (MDD) is capable of producing isobutene from 3-HMB presents an 
attractive method to produce an important platform chemical (46).  However, the activity 
of MDD on the non-native substrate (3-HMB) is far too low for commercial applications.  
We have been developing methods, such as a growth selection and a biosensor, in order 
to efficienctly identify MDD variants that produce more isobutene (Chapters 4 & 5).  In 
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addition to a robust selection system directed enzyme evolution requires a sufficient 
mutagenesis strategy.  
Extensive search of mutant variants generated by PCR random mutagenesis did 
not yield large increases in enzyme activity (see Chapter 6).  In our PCR random 
mutagenesis experiments only three or four amino acids are varied per gene.  This was 
done in order to maximize sequence diversity while balancing the need avoid excessive 
deleterious mutations.  Over four amino acid mutations per gene could lead to a large 
number of inactive enzyme.  Additionally, it is very rarely seen that the mutations 
generated by this method yield more than one nucleotide change per codon, which 
restricts the variation possible for each amino acid residue.   
One method of incorporating natural diversity is fragmentation gene shuffling 
(23, 82, 83, 93).  In this method, gene homologs or mutant libraries of a single gene are 
randomly fragmented by restriction digest into small fragments between 50 and 200 bp 
(93).  These fragments are then used to randomly reconstitute the chimeric genes.  
Although this method allows the diversity from several genes to be incorporated into one 
chimera, it has several drawbacks.  The need for the small fragments to anneal to each 
other in a PCR reaction necessitates that the gene homologs have high sequence 
homology (≥90%) to one another.  On top of this problem, the small fragments are biased 
towards priming other fragments from the same gene since they will be identical in 
sequence, so there is a high frequency of reconstituting the native parental genes.  
Finally, fragmentation based gene shuffling creates small fragments that act as primers to 
reconstitute the gene, which essentially reduces the variation found within those regions 
and results in chimeras with blocks of variation from several genes. 
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Synthetic gene shuffling is a modified form of gene shuffling that could overcome 
some of the limitations seen in fragmentation gene shuffling.  Although similar in 
concept, synthetic gene shuffling uses synthetically designed oligonucleotide fragments, 
(often about 60 bp in length), that encapsulate the diversity found in several gene 
homologs within the oligo itself.  These oligonucleotides contain regions of overlap that 
allow the chimeric gene to be reconstituted in a primerless PCR reaction.  Using synthetic 
gene shuffling, gene homologs that have very low similarity can be combined, and the 
amino acids will vary independent of the fragment length.  Also, the variation at each 
amino acid residue can be built to contain only the variation seen in the gene homologs, 
which reduces the risk of incorporating a mutation that inactivates the enzyme.  Previous 
work has indicated that the isolated variants from a fragmentation shuffled library are 
much closer to one of the parents than the wide diversity seen in a synthetic gene shuffled 
library (82).  However, destroying blocks of parental sequence that are potentially 
required for enzyme function could lead to an extremely low number of active variants 
(82).  In previous work using synthetic gene shuffling the number of active variants has 
been a sizable portion of the variant pool size (roughly 20%) (82).  This illustrates one of 
the biggest differences between fragmentation based shuffling and synthetic shuffling.  In 
fragmentation based shuffling, as many as 75% of the variants have been active in one 
study, whereas synthetic shuffling resulted in only 20%.  This difference was attributed 
mainly to technical factors such as oligonucleotide quality and was not due in large part 
to the increased number of mutations found in the chimeras (82).     
In evaluating a shuffled library, the quality is determined by the frequency a 
desired activity occurs and not by the frequency of variants with activity (82).  However, 
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the number of variants with activity can change the method with which the desired 
variant is isolated.  For libraries of shuffled genes with a high frequency of active 
variants, a screen could be used.  In our libraries where only a small number of variants 
are hypothesized to be active, a more robust method, such as a selection, will most likely 
be needed.  Careful analysis of the costs and benefits of using this method to direct 
enzyme evolution of ScMDD led us to use synthetic gene shuffling to sample the 
diversity seen within six gene homologs using our in vivo selection system. 
 
Materials and Methods 
 
Synthetic shuffling.  Oligonucleotides were designed from the yeast mevalonate 
diphosphate decarboxylase (ScMDD) gene based on variation found in the five gene 
homologs that were within 70% sequence homology to ScMDD.  Each oligo was 60 to 64 
bp in length and was ordered from Integrated DNA Technologies (IDT) in Iowa City, 
Iowa.  The entire 1,222 bp gene was reconstituted using 30 oligonucleotides; 15 in the 
forward direction (F1 – F15) and 15 in the reverse direction (R1 – R15).  Each oligo 
shares at least 20 bp of overlapping sequence with its neighboring oligonucleotide.  All 
primers except F1 and R1 (the outermost primers) were mixed in 50 µl of a primerless 
PCR reaction using KOD hotstart mastermix as the enzyme and buffer (EMD 
Biosciences).  This reaction contained approximately 100 pmol of each primer and was 
PCR amplified using a program of 95˚C for 2 min, then 30 cycles of 95˚C for 20 sec, 
48˚C for 30 sec, and 70˚C for 45 sec, followed by 3 min at 70˚C.  3 µl of this product was 
then used in a new 50 µl PCR reaction using F1 and R1 as the primers with the same run 
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program.  Product was cleaned using Promega’s Wizard PCR Clean-up System 
(Madison, WI), and digested by BglII and HindIII.  The digest was cleaned by gel 
extration and then ligated into a pET41a expression plasmid named pBE522.  This 
ligation was heat-inactivated after 16˚C overnight incubation and transformed into 
DG129 tester cells (See Chapter 5). 
Selection.  DG129 cells were grown on LB plates with 10 mM isopentenol to 
count total transformants or 10 mM mevalonate plates for the mevalonate selection.  The 
LB plates were incubated at 37˚C for several days until colonies formed.  Colonies were 
then counted and any single colonies capable of growth on mevalonate plates were 
isolated and tested. 
Analysis by gas chromatography.  Isobutene was measured by using a Varian 
450GC with a CP-Sil 5 CB column fitted with a flame ionization detector.  The method 
used a 10:1 split ratio and a 30 ml/min flow rate with helium as the carrier gas.  The oven 
was held at 30°C for 3 min, which was the duration of the method.   
 
Results 
The genetic diversity from six mevalonate diphosphate decarboxylase (MDD) 
genes was recombined by synthetic gene shuffling.  These six genes were chosen based 
on their homology to the Saccharomyces cerevisiae MDD.  All were within 70% 
sequence identity and all genes were approximately the same length.  The six were MDD 
genes from Saccharomyces cerevisiae, Kluyveromyces lactis, Candida glabrata, 
Lachancea thermotolerans, Zygosaccharomyces rouxii, and Vanderwaltozyma polyspora.   
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Variation was measured using ClustalW2 analysis (EMBL-EBI) and is shown in figure 
33. 
 
 
ZrMDD  MVYHIASTTAPVNIATLKYWGKRDKALNLPTNSSISVTLSQEDLRTLTSAATGPELKQDK 60 
VpMDD  MVY-VASTTAPVNIATLKYWGKRDKDLNLPTNSSISVTLAQEDLRTLTSAATDEGFTQDK 59 
CgMDD  MTY-VASTTAPVNIATLKYWGKRDAKLNLPTNSSISVTLAQEDLRTLTSAATSSEFKEDK 59 
LtMDD  MSIYTASTTAPVNIATLKYWGKRDKTLNLPTNSSISVTLAQEDLRTLTSVATSESFTEDQ 60 
KlMDD  MSIYSASTTAPVNIATLKYWGKRDKVLNLPTNSSISVTLSQEDLRTLTTATTSPDFAKDQ 60 
ScMDD  MTVYTASVTAPVNIATLKYWGKRDTKLNLPTNSSISVTLSQDDLRTLTSAATAPEFERDT 60 
       *    **.****************  *************:*:******:.:*   : .*  
 
ZrMDD  LWLNGKEESLESERTQQCLKGLRKLRKELEDKDSNLPKFSNWGLHIVSENNFPTAAGLAS 120 
VpMDD  LWLNGKEESLDSARTQQCLADLRGLRQQVEAQDPQAPKMSQWKLHIVSENNFPTAAGLAS 119 
CgMDD  LWLNGKEESLSSERTQNCLADLRALRRQLEEKDSSLPPMSQWKLHIVSENNFPTAAGLAS 119 
LtMDD  LWLNGQPESLQGERTQHCLQDLRNLRSRIEAQDSSLPRMSQWKLHIVSENNFPTAAGLAS 120 
KlMDD  LWLNGKEESLASERTQHCLQDLRQLRRELEEKDSSLPTFSQWKLHIASENNFPTAAGLAS 120 
ScMDD  LWLNGEPHSIDNERTQNCLRDLRQLRKEMESKDASLPTLSQWKLHIVSENNFPTAAGLAS 120 
       *****: .*: . ***:** .** ** .:* :*.. * :*:* ***.************* 
 
ZrMDD  SAAGFAALVVAIARLYQLPQSMSELSEIARQGSGSACRSLFGGYVAWEMGEKEDGSDSKA 180 
VpMDD  SAAGFAALVVAIAKLYQLPQDYSEISKIARKGSGSACRSLFGGYVAWEMGENLDGSDSKA 179 
CgMDD  SAAGFAALVMAIAKLYELPQSASDISKIARKGSGSACRSLFGGYVAWEMGEKADGSDSKA 179 
LtMDD  SAAGFAALVMAIAKLYQLPDSHSEISKIARKGSGSACRSLFGGYVAWEMGSEPDGSDSKA 180 
KlMDD  SAAGFAALIKAIAKLYELPQSESELSKIARKGSGSACRSLFGGYVAWEMGKLEDGSDSKA 180 
ScMDD  SAAGFAALVSAIAKLYQLPQSTSEISRIARKGSGSACRSLFGGYVAWEMGKAEDGHDSMA 180 
       ********: ***:**:**:. *::*.***:*******************.  ** ** * 
 
ZrMDD  VEISPLEHWPQMKAAILVVNASKKDTPSTSGMQLTVKTSELFQERVKNVVPQRFTHMKEA 240 
VpMDD  VEVAPLNHWPNMKAAILVVSDMKKDTPSTSGMQLTVKTSDLFQERIKNVVPQRFEEMKQA 239 
CgMDD  VEVAPLEHWPNMKAAVLVVSADKKDTPSTSGMQLTVNTSDLFKERITNVVPKRFEAMKKA 239 
LtMDD  VEVAPQSHWPEMKAAILVVSADRKDTPSTSGMQHTVATSDLFQERIRNVVPKRFEEMKQA 240 
KlMDD  VEIGSLNHWPEMKAAILVVSADKKDTPSTSGMQLTVKTSDLFQERINNVVPKRFEQMKKS 240 
ScMDD  VQIADSSDWPQMKACVLVVSDIKKDVSSTQGMQLTVATSELFKERIEHVVPKRFEVMRKA 240 
       *::.  ..**:***.:***.  :**..**.*** ** **:**:**: :***:**  *::: 
 
ZrMDD  IEHKNWPKFAELTMKDSNSFHATCLDSYPPIFYMNDTSKKIIKLCHAINEFYGKTVVAYT 300 
VpMDD  IRNKDFPTFADLTMKDSNSFHATCLDSYPPIFYMNDTSRKIIRLVHSINAFYNETIVAYT 299 
CgMDD  ILDKDFPTFAELTMKDSNSFHATCLDSFPPIFYINDTSKKIIKLCHLINEFYGETIVAYT 299 
LtMDD  IQDRDFTRFAELTMRDSNSFHATCLDSFPPIFYMNDTSRKIVKLCHQINAFYDETIVAYT 300 
KlMDD  ILEKDFPTFAELTMKDSNSFHATCLDSYPPIFYLNDTSKKVIKLCHAINEFYNETVVAYT 300 
ScMDD  IVEKDFATFAKETMMDSNSFHATCLDSFPPIFYMNDTSKRIISWCHTINQFYGETIVAYT 300 
       * .:::. **. ** ************:*****:****::::   * ** **.:*:**** 
 
 
 
 
 
 
 
 
 
126 
 
 
Figure 33. (continued) 
 
ZrMDD  FDAGPNAVLYYLQENEAKLFAFIYKLFDKVPGWETKFSNQDLQEFLSVYEKDVSGKLPFE 360 
VpMDD  YDAGPNAVLYYLEENESKLFAFIYKLFDKVSGWETKYTEAELNDFLKEFDQSVSPKLDFE 359 
CgMDD  YDAGPNSVLYYLEENEEKLFAFIYTLFSKVDGWQSKYNSEELSKFTSTFNNQVKGKFQFD 359 
LtMDD  FDAGPNAVLYYLQENEAKLMAFVHHVFQKNSGWDTKFSQNDLEKFSEVFKTRVAPEVAFE 360 
KlMDD  FDAGPNAVLYYLEQSEDKLFAFLYHLFQNVSGWESKFTKEQLSQFNAKFD-EIKDDVSFY 359 
ScMDD  FDAGPNAVLYYLAENESKLFAFIYKLFGSVPGWDKKFTTEQLEAFNHQFE--SSNFTARE 358 
       :*****:***** :.* **:**:: :* .  **:.*:.  :*. *   :.           
 
ZrMDD  LDDEVQNGVSRVILTQVGPGPLSTKESLIDENTGLPK- 397 
VpMDD  LDDEIYRGVSRVILTRAGPGPQDTTECLIDENTGLPK- 396 
CgMDD  LDDTIQENVSRVILTRVGPGPQDTKECLINEETGLPK- 396 
LtMDD  FDEELYKGVSRVILTQVGPGPQDTTECLINKSTGYPN- 397 
KlMDD  LDSELHQGVTRVILTRVGPGPQDTDLSLIDSATGLPSN 397 
ScMDD  LDLELQKDVARVILTQVGSGPQETNESLIDAKTGLPKE 396 
       :*  : ..*:*****:.*.** .*  .**:  ** *.  
 
Fig. 33. ClustalW analysis of ScMDD along with five homologs. 
 
 
The information from ClustalW2 indicated which residues were conserved throughout all 
six genes (stars), which varied only slightly (two dots), and which residues had large 
amounts of variation throughout the six genes (one or no dots).  This information was 
combined onto a ScMDD template to map the desired amino acid residues to target for 
shuffling, and was combined with known information of critical catalytic and binding 
sites in the MDD enzyme (Fig. 34). 
 
 ScMDD Amino Acid Sequence: 
MTVYTASVTAPVNIATLKYWGKRDTKLNLPTNSSISVTLSQDDLRTLTSAATAPEFERDT
LWLNGEPHSIDNERTQNCLRDLRQLRKEMESKDASLPTLSQWKLHIVSENNFPTAAGLA
SSAAGFAALVSAIAKLYQLPQSTSEISRIARKGSGSACRSLFGGYVAWEMGKAEDGHDS
MAVQIADSSDWPQMKACVLVVSDIKKDVSSTQGMQLTVATSELFKERIEHVVPKRFEV
MRKAIVEKDFATFAKETMMDSNSFHATCLDSFPPIFYMNDTSKRIISWCHTINQFYGETIV
AYTFDAGPNAVLYYLAENESKLFAFIYKLFGSVPGWDKKFTTEQLEAFNHQFESSNFTAR
ELDLELQKDVARVILTQVGSGPQETNESLIDAKTGLPKE 
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FIG. 34. The amino acid sequence of ScMDD with important residues highlighted.  In this color-
coded representation of the ScMDD enzyme, yellow highlights indicate residues that vary for 
Zygosaccharomyces rouxii (Zr), Vanderwaltozyma polyspora (Vp), Candida glabrata (Cg), 
Lachancea thermotolerans (Lt), Kluyveromyces lactis (Kl), and ScMDD genes, purple indicates 
variation in some but not all of the genes, red color indicates required catalytic residues, and 
green indicates binding site residues.  Additionally, light blue indicates residues that are within H-
bond forming distance of mevalonate diphosphate (MDP) or ATP (possible binding site residues) 
and dark blue indicates residues that are proposed to interact with the terminal phosphate group.   
 
The next step was to decide which residues to alter.  Although mutating strictly 
conserved residues could lead to a desired mutant, it also has a high chance of producing 
an enzyme with no activity.  A better target was residues that varied throughout all six 
gene homologs but to incorporate all of the diversity seen was too complex.  There were 
too many sites to vary and, at sites that had greater than 3 amino acids representing them 
throughout the six homologs, the degeneracy needed to produce the amino acid variation 
becomes quite large.  Additionally, if several degenerate nucleotides are needed to 
sample all of the amino acids present, this greatly increases the chance of incorporating 
an amino acid that is not represented in the six homologs, which will increase the chance 
of a deleterious mutation occurring in the product.  To alleviate these problems, only 
residues that contained between two or three amino acid differences for the six genes 
were targeted for synthetic gene shuffling (residues shown in purple in Fig. 34).  Some of 
the critical active site residues were also varied, but were only a small fraction of the 
targeted sites.  The 30 oligonucleotides designed for synthetic gene shuffling are shown 
(Table 9).  Standard degenerate code is used to indicate nucleotides that are varied in 
order to incorporate the variation seen in the six genes.  All changes were done with E. 
coli codon usage bias where possible.  Also, in some cases additional nucleotides were 
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added to the 60 bp oligonucleotide in order to raise the annealing temperature of all 
fragments above 50˚C.  This was done out of an abundance of caution to ensure that each 
oligonucleotide properly primed the next fragment during primerless PCR.  Figure 4 
shows the ScMDD amino acid sequence with residues highlighted and made bold that 
will vary given the changes built in to the oligonucleotides.  
 
 
 
 
TABLE 9. Oligonucleotide sequences for the 30 oligos used in the synthetic gene shuffling of 
MDD.  All oligo sequences are 5’ to 3’. 
 
 
Gel confirmation of reconstituted MDD.  After primerless PCR was used to 
assemble the oligos, the product was added to a new PCR reaction with flanking primers.  
Following PCR amplification, a small amount of the product was applied to a 1% agarose 
gel for visualization of the PCR product (Fig. 35).  The only PCR product is 
approximately 1200 bp in length, which is the correct size for MDD (1222 bp).  The rest 
Oligonucleotide sequences
F1: gccgcc AGATCTATGCATCATCATCATCATCATATGACCGTGTATACCGCGAGCGTGACC
F2: CCTGAAANNTTGGGGCAAACGTGATACCAAACTGAACCTGCCGACCAACAGCAGCATTAG
F3: ATCTGCGTACCCTGACCAGCGYGRCGACCGCGCCGGAAYTTGAACGTGATACCCTGTGGC
F4: AGCATTGATRRCGAANGTACCCAGMAHTGCCTGCGTGRTCTGCGTCAGCTGCGTAAAGAAATGG
F5: GCCGACCHTKAGCCAGTGGAAACTGCATATTGYGAGCGAAAACAACTTTCCGACCGCAGC
F6: CAGGTTTTGCAGCACTGGTTAGCGCGATTGCGMRWCTGTATCAGCTGCCGSAKAGCACCA
F7: CGTAAAGGCAGCGNCAGCGCGTGCCGTAGCCTGTTTGGCGGCTATGTGGCGTGGGAAATG
F8: TGATAGCATGGCGGTGCAGATTGSGGATAGCRRHGMTTGGCCGCAGATGAAAGCGTGCGT
F9: TCAAGAAAGATRYGMSCAGCACCYMGGGCATGCAGCTGACCGTGGCGACCAGCGAWCTGTTTA
F10: GTGCCGMAACGTTTTGAAGTGATGCGTVARKCGATTGTGGAAAAAGATTKKGCGACCTTTGC
F11: TAGCAACAGCTTTCATGCGACCTGCCTGGATAGCTWTCCGCCGATCTTCTACATGAACGATAC
F12: GCTGGTGCCATACCATTAACCAGTTTTATRRCRAAACCRTTGTGGCGTATACCTTTGATG
F13: TATTATCTGGCGSAAAACGAAAGCAAACTGWTKGCGTTTVTTTATAAACTGTTTGGCAGCGTG
F14: ATTTACCACCGAACAGCTGGAAGCGTTTAACCATCAGTWTGAAAGCAGCAACTTTACCGC
F15: TGCAGANAGRTGTGGCGCGTGTGATTCTGACCCRWGYGGGCAGCGGCCCGCAGGAAACCA
R1: gccgcc AAGCTTACTCTTTCGGCAGGCCGGTTTTCGCATCAATCAGGCTTTCGTTGGTTTCCTGCGGGCCGCTG
R2: ACGCGCCACAYCTNTCTGCAGTTCCAGATCMARTTCACGCGCGGTAAAGTTGCTGCTTTC
R3: CCAGCTGTTCGGTGGTAAATTTTKWWTCCCAGCCCGGCACGCTGCCAAACAGTTTATAAA
R4: TCGTTTTSCGCCAGATAATACAGCACCGMGTTCGGGCCCGCATCAAAGGTATACGCCACA
R5: GTTAATGGTATGGCACCAGCTAAYAAYACGTTTGCTGGTATCGTTCATGTAGAAGATCGG
R6: TCGCATGAAAGCTGTTGCTATCCATCATGGTTTCWTYCGCAAAGGTCGCMMAATCTTTTT
R7: ACTTCAAAACGTTKCGGCACCACATGTTCAATACGTTCTTTAAACAGWTCGCTGGTCGCC
R8: GGTGCTGSKCRYATCTTTCTTGATATCGYTGACCACCAGAACGCACGCTTTCATCTGCGG
R9: TCTGCACCGCCATGCTATCATGGCCATCTTCCGCKYYGCCCATTTCCCACGCCACATAGC
R10: GCGCTGNCGCTGCCTTTACGCGCAATACGGCTAATTTCGCTGGTGCTMTSCGGCAGCTGA
R11: AACCAGTGCTGCAAAACCTGCTGCGCTGCTTGCCAGACCTGCTGCGGTCGGAAAGTTGTT
R12: TCCACTGGCTMADGGTCGGCAGGYKCGYATCTTKGCTTTCCATTTCTTTACGCAGCTGAC
R13: TGGGTACNTTCGYYATCAATGCTATGCGGTTYGCCGTTCAGCCACAGGGTATCACGTTCA
R14: GCTGGTCAGGGTACGCAGATCATCCTGGSYCAGGGTCACGCTAATGCTGCTGTTGGTCGG
R15: GTTTGCCCCAANNTTTCAGGGTCGCAATGTTCACCGGCGCGGTCACGCTCGCGGTATACA
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of the PCR product was wizard cleaned (Promega), and then digested using BglII and 
HindIII restriction enzymes.  The product was run on a 1% agarose gel and extracted 
before ligating into the pET41a derived pBE522 vector and transformation into DH5α E. 
coli cells.  
 
 
 
 
FIG. 35. A 1% agarose gel was used to confirm the reconstitution of MDD during synthetic gene 
shuffling experiments.  The product of the PCR amplification using ScMVDC-F and ScMVDC-R 
primers was run on a gel in both lanes.  The only band seen in the product is the correct size 
(1222 bp) for reconstituted MDD. 
 
 
 
Sequencing of the shuffled insert.  15 random clones were isolated and 
sequenced to confirm that the MDD gene was present.  The sequencing indicated that the 
1222 bp
Kb               MDD             MDD
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synthetically shuffled MDD gene is present in all clones analyzed with a large amount of 
variation, but that there are also numerous missing or inserted bases, which result in 
frameshifts.  Out of the 15 sequences, only 2 did not have a frameshift.  This was 
anticipated due to the errors inherent in oligonucleotide synthesis, but it makes the 
discovery of an improved variant more challenging since frameshifts are likely to 
produce inactive enzyme.  An average of 18 mutations per MDD gene was seen in this 
synthetic gene shuffling library. 
 
Discussion 
In chapter 4 mutagenic PCR was used to introduce mutations into the ScMDD 
gene and an isopentenol-dependent E. coli strain was used to select for variants capable 
of converting mevalonate to isopentenol.  Although the selection works, it is apparent 
that the three or four mutations per gene that mutagenic PCR introduces into MDD may 
not be enough to change the enzymes substrate specificity and allow for growth on 
mevalonate.  Synthetic gene shuffling allows us to quickly expand the sequence diversity 
of the gene.  For this reason, we turned to gene shuffling, a method that has previously 
been shown to increase enzyme activity by over 10,000-fold (16), in order to improve 
MDD by several orders of magnitude.  Our results demonstrate that synthetic gene 
shuffling is a viable method to creating multi-gene chimeras of MDD.  However, we have 
also confirmed and shown that errors that occur during oligonucleotide synthesis lead to 
large numbers of genes with at least one or more nucleotide insertions or deletions.  
Additionally, out of over 200,000 variants selected for on mevalonate, none have been 
capable of mevalonate-dependent growth.  Part of the limitation of this strategy is the 
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number of inactive variants, which essentially limits the 200,000 variants screened to 
approximately 26,000 potentially active variants.  Future work should attempt to limit 
this problem, either through the improvement of oligonucleotide synthesis in order to 
reduce errors that lead to frameshit mutations, or by using strategies that balance the 
mutagenesis of the gene with reduction of these error rates.  This second approach could 
take the form of using more wild-type oligos in the PCR reactions to reconstitute the 
chimeric MDD genes.  For example, out of the 30 oligonucleotides used for the synthesis 
of MDD in this report, perhaps 15 could be made with wild-type ScMDD sequence.  
These wild-type oligos would all have the same sequence and so could be PAGE purified 
during synthesis, which would drastically reduce the number of fragments that have 
nucleotide errors.  This method would reduce the number of mutations created in the 
chimeras, but would also lead to a larger number of full length MDD genes.  Other ways 
to improve the method will include lowering the stringency of the mevalonate selection, 
possibly through small supplementation of isopentenol, or through batch culture 
enrichment, all of which is discussed in more detail in chapter 5.   
Although limitations still exist, this study has shown that synthetically designed 
oligonucleotide fragments can be used to fully reconstitute chimeric MDD genes for use 
in our mevalonate selection systems.  However, the isolation of mutants with enhanced 
activity will only be the first step in our gene shuffling protocols.  To achieve higher 
enzyme fitness, several rounds of gene shuffling will be needed where in each round the 
diversity that led to improved enzyme varieties is used to design new oligonucleotide 
fragments.  By combining the improvement in sequence diversity created by synthetic 
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gene shuffling with our in vivo selection method we should improve the efficiency and 
frequency of isolating variants with higher isobutene-forming capabilities.   
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Chapter 7. Conclusion and Future Work 
 
The discovery of mevalonate diphosphate decarboxylase’s isobutene-forming 
activity is a key step in establishing the bio-based production of an important industrial 
molecule.  However, the improvement in enzyme activity on the non-native substrate (3-
HMB) needs to be improved several orders of magnitude before commercial application 
is feasible.  Future work will focus on increasing enzyme activity as well as the 
development of ways to efficiently produce 3-HMB from renewable feedstocks such as 
glucose.   
 
I. 3-HMB synthesis 
Our long term goal is the production of 3-HMB to be integrated into a host, such 
as E. coli, for the biological production of isobutene from renewable carbon.  However, 
our current isobutene-forming system uses exogenously supplied 3-HMB.  3-HMB is 
currently used as a nutritional supplement and it has been found to have a positive effect 
on lean muscle maintenance as well as potentially positive effects on the body’s immune 
response (56).  3-HMB is naturally produced in humans and animals as a product of 
leucine degradation via ketoisocaproate (65).  However, the commercial production of 3-
HMB is currently done through chemical synthesis (21).  This process uses the sodium 
hypochlorite-catalyzed oxidation of diacetone alcohol to produce 3-HMB (65).  Although 
this process can be used for the production of 3-HMB, the process is energy intensive, it 
uses compounds derived from petroleum, and it creates free-radicals that can harm the 
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environment (65).  For this reason, an enzymatic route to 3-HMB may be a more cost-
effective and environmentally friendly method to produce 3-HMB. 
A biological route for the production of 3-HMB at high yields was found in the 
fungus Galactomyces reessii, where titers of 3-HMB reached 38 g/L via the conversion 
of β-methylbutyric acid (65).  This level of 3-HMB synthesis was achieved through the 
exogenous addition of β-methylbutyric acid (MBA) but at the time the exact route to 
produce 3-HMB was unknown (65).  Researchers hypothesized that one possible pathway 
uses acyl-CoA synthetase to convert MBA to the CoA derivative (65).  Researchers 
hypothesized that acyl-CoA dehydrogenase could convert MBA-CoA into 
methylcrotonyl-CoA, followed by hydration to HMB-CoA via an enoyl-CoA hydratase.  
Hydrolysis of the CoA would then yield HMB (65).   
The enzyme responsible for 3-HMB synthesis was subsequently isolated and 
characterized from Galactomyces reessii (30) and found to be an enoyl-CoA hydratase 
that converts methylcrotonyl-CoA to HMB-CoA, as hypothesized by Lee et al. (30, 65) 
(Fig. 36).  It was further found that this 3-HMB pathway operates in microbes, such as G. 
reessii, in a similar fashion to animals.  However, the primary step from 3-methylbutyrate 
(MBA) to isovaleryl-CoA via an acyl-CoA synthetase differs from the animal pathway, 
which relies on leucine degradation (66).  
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FIG. 36. All three potential 3-HMB pathways are shown.  The Leucine pathway (green), Valine 
pathway (blue), and Homoacetogen pathway (red), all merge at methycrotonyl-CoA to produce 3-
HMB.  Dashed pathways are enzyme pathways found in mammals in the leucine degradation 
pathway, including α-ketoisocaproate oxygenase and β-methylbutyric acid hydroxylase. 
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From that point, however, the two pathways merge from MBA or leucine degradation 
(66).  Isovaleryl-CoA is then converted to methylcrotonyl-CoA by the isovaleryl-CoA 
dehydrogenase, then to 3-hydroxy-3-methylbutyryl-CoA by the enoyl-CoA hydratase 
identified by Dhar et al. (30).  The 3-hydroxy-3-methylbutyryl-CoA is then hydrolyzed to 
form HMB (30).  Additionally, acetyl-CoA, propionyl-CoA, and acetoacetyl-CoA were 
found to be competitive inhibitors of the enoyl-CoA hydratase.   
The leucine degradation pathway to form 3-HMB is an interesting method for in 
vivo 3-HMB production.  The in vivo production of 3-HMB could possibly be a more 
cost-effective and environmentally friendly way to make the large amounts of 3-HMB 
needed for the MDD catalyzed reaction to isobutene.  Additionally, producing 3-HMB in 
a cell rather than providing it exogenously could increase the apparent intracellular 
concentration of 3-HMB, thereby increasing the amount of isobutene produced.  For this 
reason, we have investigated the utility of other pathways besides the leucine degradation 
pathway described above.  These potential pathways include the production of 3-HMB 
from glucose via acetyl-CoA in a homoacetogen or from a proposed pathway from 
valine.   
In the proposed valine pathway, valine would be converted to α-ketoisovalerate 
(KI), followed by the reduction to α-hydroxyisovalerate (HI) (Fig. 36).  A reduction from 
α-hydroxyisovalerate to methylcrotonate (MC) yields a substrate capable of being 
converted to 3-HMB by the enoyl-CoA hydratase from G. reessii, which was identified in 
the leucine degradation pathway (Fig. 36).  In this scenario, an acyl-CoA synthetase 
might be needed for enzyme activity.  A homoacetogen could utilize acetyl-CoA to make 
137 
 
 
3-HMB as described previously (46).  In this pathway the homoacetogen would produce 
acetyl-CoA via glucose.  Two acetyl-CoA molecules would then be condensed via a 
thiolase to form acetoacetyl-CoA (Fig.1) (Chapter 3, Fig. 13).  Acetoacetyl-CoA is then 
condensed with a third acetyl-CoA to form 3-hydroxy-3-methylglutaryl-CoA (HMG-
CoA) via HMG-CoA synthase.  Methylglutaconyl-CoA hydratase and 3-methylcrotonyl-
CoA carboxylase are enzymes identified in Myxococcus species that can produce 
methylcrotonyl-CoA from HMG-CoA (8).  From methylcrotonyl-CoA, the enoyl-CoA 
hydratase from G. reessii could then be used to produce 3-HMB.  Although this pathway 
could be engineered in a homoacetogen, the engineering could be difficult due to the 
relatively few genetic tools known for these organisms and their slow growth.  However, 
if it could be introduced into a homoacetogen, we calculate that this pathway would have 
a high (90%) theoretical enthalpy of combustion yield (46).  Thus the pathway could be 
considerably more efficient than the leucine degradation pathway, which uses 1.5 
molecules of glucose to produce one molecule of isobutene, five CO2 molecules, and 5 
reducing equivalents (46).  Since there is no clear way to recover the reducing 
equivalents in the leucine degradation pathway the acetyl-CoA pathway could potentially 
be an efficient method to produce 3-HMB.  Ultimately the production of 3-HMB in vivo 
is important and the careful consideration of potential pathways will raise the probability 
of building a balanced, efficient pathway. 
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II. Search for mevalonate monophosphate decarboxylase. 
The two important factors in developing an isobutene-forming system are the high 
level production of the 3-HMB substrate and a highly efficient enzyme to produce 
isobutene.  Enzyme efficiency is still too low and the needed increase in MDD activity is 
large – nearly 6 orders of magnitude.  Although our mutagenesis efforts have yielded 
increases in isobutene-forming activity, we continue to look for a more efficient enzyme.  
One potential enzyme that could have higher activity on 3-HMB is a putative mevalonate 
monophosphate decarboxylase in archaea.  This enzyme is hypothesized to have native 
substrate specificity to mevalonate phosphate, which is closer in size and characteristics 
to 3-HMB than the native substrate of MDD (mevalonate diphosphate), and so a 
mevalonate monophosphate decarboxylase might have higher activity on 3-HMB.  
Although our primary goal of finding a mevalonate monophosphate decarboxylase 
(MPD) is to find an enzyme with higher isobutene-forming activity, the discovery of the 
MPD itself would be of large scientific significance.  As noted in the literature review, 
most archaea do not have any known mevalonate pathway (MVA) or methylerityritol 
phosphate pathway (MEP) even though they are prodigious isoprenoid producers.  Even 
though enzymatic activity has been identified that apparently contributes to a 
monophosphate decarboxylase pathway, such as isopentenyl phosphate kinase (IPK), 
there is no apparent homology found in archaea to any MDD genes (25). 
For this reason, the discovery of the MPD pathway could provide an enzyme that 
produces more isobutene from 3-HMB and also elucidate a critical enzyme pathway in 
archaea that would represent a third distinct method to produce essential isoprenoids.  We 
139 
 
 
believe we are in a unique position to find and verify an archaeal MPD.  The E. coli 
engineered for mevalonate dependence have also been engineered, in some cases, to 
express the mevalonate kinase (MVK) enzyme from Saccharomyces cerevisiae, which 
produces mevalonate phosphate from mevalonate.  This strain is also transformed with a 
cosmid carrying an archaeal gene library built from Methanosarcina acetivorans.  If a 
mevalonate monophosphate decarboxylase is present in the cosmid, then it should be 
capable of decarboxylating the mevalonate phosphate into isopentenyl phosphate, which 
in turn would be phosphorylated by the IPK present in the chromosome and allow for 
growth.  In this way we have a unique selection system to identify the putative MPD in 
M. acetivorans based on a mevalonate growth selection.  Additionally, this system will 
also verify any MPD enzymes by showing a mevalonate growth dependence only when 
the MPD is present.  In this system, the growth selection will identify the cosmid where 
the putative MPD is located.  At that point, the 40 kb M. acetivorans fragment in the 
cosmid will be randomly digested and subcloned into an expression vector and retested 
for mevalonate-dependent growth.  Although the cosmid-based screening method is the 
most efficient way to analyze the entire M. acetivorans genome, it could also raise some 
challenges for the selection.  The selection relies on M. acetivorans promoters to 
heterologously express the genes in E. coli.  Previous reports have indicated that M. 
acetivorans enzymes are difficult to express in E. coli, potentially complicating our 
efforts. 
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III. Additional increases in enzyme activity (Biosensor) 
The biggest barrier we face to large-scale isobutene production is the low activity 
that MDD has on 3-HMB.  Although the discovery of a MPD could bring an enzyme 
with higher activity, the necessary improvement in activity is so large that a robust 
selection system is needed.  The E. coli based mevalonate selection is a critical 
component in this increase, but it relies on selection mutants that have higher activity to 
decarboxylate mevalonate, not 3-HMB.  Ultimately, the creation of a robust selection, 
based on the production of isobutene, will be needed.  This selection will use an 
isobutene biosensor that can detect isobutene via a transcriptional activator.  The 
importance of this biosensor cannot be overestimated.  An efficient isobutene selection 
system will be critical not only for improving our system, but it also holds the potential to 
screen metagenomic libraries to discover other isobutene-forming enzymes that have not 
yet been identified.   
The first steps to build this isobutene biosensor have been documented in this 
study.  The transcriptional activator TbuT is able to respond to isobutene and increase 
reporter gene expression.  Barriers to implementation of this biosensor are the low 
induction ratio and low sensitivity of the system.  Both of which can be improved through 
mutagenesis and screening for an improved biosensor.  Once this improved system is 
identified, a two plasmid E. coli strain will be built for the in vivo expression of mutated 
MDD along with the biosensor-based expression of an antibiotic resistant gene such as 
tetracycline resistance (TetA) (Fig. 37).  With this system in place the efficient 
enhancement of MDD could be a possibility.   
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FIG. 37. The two plasmid system for an E. coli based biosensor that detects isobutene production 
from MDD .  Isobutene is detected by the transcriptional activator that causes transcription of the 
reporter gene, in this case it is the antibiotic resistant gene TetA, which allows for tetracycline 
resistant growth. 
 
IV. Directed evolution by mevalonate selection 
So far the emphasis of this work has been to develop the tools needed for a robust 
selection of improved MDD variants.  The mevalonate-based selection strategy has used 
plate-based growth analysis to isolate mutants with improved growth phenotypes on 
mevalonate.  However, this method involves many tedious steps to produce the mutant 
DNA and select for the variants, and the process would be improved by leveraging the 
natural selective pressure of growing cells in a batch culture.  In this method, E. coli 
expressing wild-type or mutated MDD would be inoculated into a large volume of 
growth medium containing mevalonate and very small amounts of isopentenol.  The 
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isopentenol is enough for slow cell growth (such as a doubling time of 8 hours).  This 
slow growth allows mutations to naturally accumulate in the MDD gene and variants 
with mutations that improve their ability to decarboxylate mevalonate will have an 
increased growth rate.  An increase in growth rate allows that cell line to quickly overtake 
the culture and then that mutant can easily be identified and isolated.   
The reason we have not adopted this method is due to the relatively high 
frequency of revertants that bypass the mevalonate selection and grow independent of 
mevalonate.  These revertants grow much more quickly than the other cells and quickly 
overtake the culture.  Although we continue to investigate the cause of these reversions, 
we hypothesize that some enzyme or intermediate in the MEP pathway contributes to 
overcoming the deletion of lytB and allows for growth under certain circumstances.  This 
hypothesis has been tested by using the antibiotic fosmidomycin, which inhibits the DXP 
reductoisomerase of the MEP pathway.  Fosmidomycin was used successfully to inhibit 
the growth of all revertants tested, which indicates that most if not all of the revertants are 
most likely due to some upstream intermediate of the MEP pathway. 
Tests with fosmidomycin have indicated that if a majority of the revertants are 
sensitive to this antibiotic, it may be possible to develop large batch growth cultures in 
order to isolate improved mutants.  If this proves to be the case, then the elimination of 
MEP pathway intermediates, such as by deleting upstream MEP pathway genes in E. coli, 
might provide a more permanent, cost effective way to control revertants than using 
fosmidomycin.  To investigate this possibility, an upstream MEP pathway gene has been 
identified as a candidate for deletion.  The IspD gene expresses the 4-diphosphocytidyl-2-
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C-methyl-D-erythritol synthase, which is just downstream of the DXP reductoisomerase 
(Fig. 6).  Elimination of this gene will be done using the Wanner method, similar to the 
way that lytB was knocked out.  The IspD knockout should eliminate the buildup of MEP 
pathway intermediates in E. coli, which is mostly likely responsible for the revertants.  If 
successful, this system should allow us to isolate mutants using batch growth, which will 
significantly increase our abilities to select for large numbers of variants (>106 variants). 
The development of MDD as an isobutene-forming enzyme represents an 
important component of the enzymatic production of fuels and chemicals.  However, 
much work remains to improve the enzyme to levels capable of meaningful production.  
With the techniques described and developed in this thesis, we feel that the improvements 
of MDD are possible.   
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ABBREVIATIONS 
LB: Luria-Bertani; IPTG: isopropyl β-D-1-thiogalactopyranoside; GC: gas 
chromatography; SDS-PAGE: sodium dodecyl sulfate polyacrylamide gel 
electrophoresis; NAD+/NADH: nicotinamide adenine dinucleotide. OD600: optical density 
at 600 nm; TCA: tricarboxylic acid; MDD: mevalonate diphosphate decarboxylase; 
MPD: mevalonate monophosphate decarboxylase; 3-HMB: 3-hydroxy-3-methylbutyrate; 
IPK: isopentenyl phosphate kinase; IDI: isopentenyl diphosphate isomerase; IPP: 
isopentenyl diphosphate; MEP pathway: Methylerythritol phosphate pathway; MVA 
pathway: Mevalonate pathway; IEA: International Energy Agency;  
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